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The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), 
manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-
neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and 
guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 
patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized 
authentic SARS-CoV-2 with IC50 of 3.1 ng/ml. Crystal structures of two mAbs in complex with the 
SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 Å revealed a direct block of ACE2 
attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with 
mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters 
from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive 
virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy. 
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The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started emerging in humans in 
late 2019, and rapidly spread to a pandemic with millions of cases worldwide. SARS-CoV-2 infections 
cause coronavirus disease 2019 (COVID-19) with severe respiratory symptoms, but also pathological 
inflammation and multi-organ dysfunction, including acute respiratory distress syndrome, 
cardiovascular events, coagulopathies and neurological symptoms (Helms et al., 2020; Zhou et al., 
2020; Zhu et al., 2020). Some aspects of the diverse clinical manifestations may result from a 
hyperinflammatory response, as suggested by reduced mortality in hospitalized COVID-19 patients 
under dexamethasone therapy (Horby et al., 2020). 
Understanding the immune response to SARS-CoV-2 therefore is of utmost importance. Multiple 
recombinant SARS-CoV-2 mAbs from convalescent patients have been reported (Brouwer et al., 
2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 2020; Robbiani et al., 2020; Rogers et al., 2020; 
Wec et al., 2020). mAbs targeting the receptor-binding domain (RBD) of the viral spike protein S1 can 
compete with its binding to human angiotensin converting enzyme 2 (ACE2) and prevent viral entry 
and subsequent replication (Cao et al., 2020; Ju et al., 2020; Walls et al., 2020). Potent virus 
neutralizing mAbs that were isolated from diverse variable immunoglobulin (Ig) genes typically carry 
low levels of somatic hypermutations (SHM). Several of these neutralizing mAbs selected for in vitro 
efficacy showed prophylactic or therapeutic potential in animal models (Cao et al., 2020; Liu et al., 
2020; Rogers et al., 2020; Zost et al., 2020). The low number of SHM suggests limited affinity-
maturation in germinal centers compatible with an acute infection. Near-germline mAbs usually 
constitute the first line of defense to pathogens, but carry the risk of self-reactivity to autoantigens 
(Lerner, 2016; Liao et al., 2011; Zhou et al., 2007). Although critical for the therapeutic use in 
humans, potential potential tissue-reactivity of near-germline SARS-CoV-2 antibodies has not been 
examined so far. 
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Here, we systematically selected 18 strongly neutralizing mAbs out of 598 antibodies from 10 COVID-
19 patients by characterization of their biophysical properties, authentic SARS-CoV-2 neutralization, 
and exclusion of off-target binding to murine tissue. Additionally, we solved two crystal structures of 
neutralizing mAbs in complex with the RBD, showing antibody engagement with the ACE2 binding 
site from different approach angles. Finally, we selected mAb CV07-209 by its in vitro efficacy and the 
absence of tissue-reactivity for in vivo evaluation. Systemic application of CV07-209 in a hamster 
model of SARS-CoV-2 infection led to profound reduction of clinical, paraclinical and histopathological 
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Antibody repertoire analysis of COVID-19 patients 
We first characterized the B cell response in COVID-19 using single-cell Ig gene sequencing of 
human mAbs (Fig. 1A). From ten COVID-19 patients with serum antibodies to the S1 subunit of the 
SARS-CoV-2 spike protein (Fig. S1, Supplementary Table ST1), we isolated two populations of single 
cells from peripheral blood mononuclear cells with fluorescence-activated cell sorting (FACS): 
CD19+CD27+CD38+ antibody secreting cells (ASC) reflecting the unbiased humoral immune response 
and SARS-CoV-2-S1-labeled CD19+CD27+ memory B cells (S1-MBC) for characterization of antigen-
specific responses (Fig. S2A and S2B). We obtained 598 functional paired heavy and light chain Ig 
sequences (Supplementary Table ST2). Of 432 recombinantly expressed mAbs, 122 were reactive to 
SARS-CoV-2-S1 (S1+), with a frequency of 0.0-18.2% (median 7.1%) within ASC and 16.7-84.1% 
(median 67.1%) within S1-MBC (Fig. 1B and 1C). Binding to S1 did not depend on affinity maturation 
as measured by the number of SHM (Fig. 1D). Compared to mAbs not reactive to SARS-CoV-2-S1, 
S1+ mAbs had less SHM, but equal lengths for both their light and heavy chain complementarity-
determining region 3 (CDR3) (Fig. S2C, S2D and S2E). Within the ASC and S1-MBC population, 
45.0% and 90.2% of S1+ mAbs bound the RBD, respectively (Fig. S2F).  
S1+ mAbs were enriched in certain Ig genes including VH1-2, VH3-53, VH3-66, VK1-33 and VL2-14 
(Fig. S3). We identified both clonally related antibody clones within patients and public and shared 
S1+ clonotypes from multiple patients (Fig. S4). Some public or shared clonotypes had been 
previously reported, such as IGHV3-53 and IGHV3-66 (Supplementary Table ST3) (Cao et al., 2020; 
Yuan et al., 2020a), while others were newly identified, such as IGHV3-11 (Fig. S4C). 
 
Identification and characterization of potent SARS-CoV-2 neutralizing mAbs 
We next determined the mAbs with the highest capacity to neutralize SARS-CoV-2 in a plaque 
reduction neutralization tests (PRNT) using authentic virus (Munich isolate 984) (Wolfel et al., 2020). 
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Of 86 mAbs strongly binding to RBD, 40 showed virus neutralization with a half-maximal inhibitory 
concentration (IC50) ≤250 ng/ml and were considered neutralizing antibodies (Fig. 1A, Supplementary 
Table ST2), from which 18 (Top-18) were selected for further characterization (Supplementary Table 
ST4). The antibodies bound to RBD with a half-maximal effective concentration (EC50) of 3.8-14.2 
ng/ml (Fig. 1E) and an equilibrium dissociation constant (KD) of 6.0 pM to 1.1 nM (Fig. S5, 
Supplementary Table ST4), thereby neutralizing SARS-CoV-2 with an IC50 of 3.1-172 ng/ml (Fig. 1F, 
Supplementary Table ST4). The antibody with the highest affinity, CV07-209, was also the strongest 
neutralizer (Fig. 1G). We hypothesized that the differences in neutralizing capacity relate to different 
interactions with the ACE2 binding site. Indeed, the strongest neutralizing mAbs CV07-209 and 
CV07-250 reduced ACE2 binding to RBD to 12.4% and 58.3%, respectively. Other Top-18 mAbs 
including CV07-270 interfered only weakly with ACE2 binding (Fig. S6A).  
The spike proteins of SARS-CoV-2 and SARS-CoV share more than 70% amino acid sequence 
identity, whereas sequence identity between SARS-CoV-2 and MERS-CoV and other endemic 
coronaviruses is significantly lower (Barnes et al., 2020). To analyze potential cross-reactivity of 
mAbs to other coronaviruses, we tested for binding of the Top-18 mAbs to the RBD of SARS-CoV, 
MERS-CoV, and the human endemic coronaviruses 229-E, NL63, HKU1 and OC32. CV38-142 
detected the RBD of both SARS-CoV-2 and SARS-CoV, whereas no other mAb was cross-reactive to 
additional coronaviruses (Fig. S7). To further characterize the epitope of neutralizing mAbs, we 
performed ELISA-based epitope binning experiments using biotinylated antibodies. Co-applications of 
paired mAbs showed competition of most neutralizing antibodies for RBD binding (Fig. S6B). As an 
exception, SARS-CoV cross-reactive CV38-142 bound RBD irrespective of the presence of other 
mAbs, suggesting an independent and conserved target epitope (Fig. S6B).  
 
Near-germline SARS-CoV-2 neutralizing antibodies can bind to murine tissue 
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Many SARS-CoV-2 neutralizing mAbs carry few SHM or are in germline-configuration (Fig. 1D) (Ju et 
al., 2020; Kreer et al., 2020). Such antibodies close to germline might be reactive to more than one 
target (Zhou et al., 2007). Prompted by the abundance of near-germline SARS-CoV-2 antibodies and 
to exclude potential side-effects of mAb treatment, we next analyzed whether SARS-CoV-2 
antibodies can bind to self-antigens. 
Therefore, we tested the binding of S1-mAbs to unfixed murine tissues. Surprisingly, four of the Top-
18 potent SARS-CoV-2 neutralizing mAbs showed anatomically distinct tissue reactivities (Fig. 2, 
Supplementary Table ST4). CV07-200 intensively stained brain sections in the hippocampal 
formation, olfactory bulb, cerebral cortex and basal ganglia (Fig. 2A). CV07-222 also bound to brain 
tissue, as well as to smooth muscle (Fig. 2B). CV07-255 and CV07-270 were reactive to smooth 
muscle from sections of lung, heart, kidney and colon, but not liver (Fig. 2C and 2D, Supplementary 
Table ST4). None of the Top-18 mAbs bound to HEp-2 cells, cardiolipin or beta-2 microglobulin as 
established polyreactivity-related antigens (Jardine et al., 2016) (Fig. S8).  
 
Crystal structures of two mAbs approaching the ACE2 binding site from different angles  
For further characterization using X-ray crystallography, we selected two neutralizing mAbs CV07-
250 and CV07-270 based on differences in the number of SHM, extent of ACE2 competition and 
binding to murine tissue. CV07-250 (IC50=3.5 ng/ml) had 33 SHM (17/16 on heavy and light chain, 
respectively), strongly reduced ACE2 binding and showed no binding to murine tissue. In contrast, 
CV07-270 (IC50= 82.3 ng/ml) had only 2 SHM (2/0), did not reduce ACE2 binding in our assay, and 
showed binding to smooth muscle tissue. Using X-ray crystallography, we determined structures of 
CV07-250 and CV07-270 in complex with SARS-CoV-2 RBD to resolutions of 2.55 and 2.70 Å, 
respectively (Fig. 3, Supplementary Tables ST5 and ST6).  
The binding mode of CV07-250 to RBD is unusual in that it is dominated by the light chain (Fig. 3A 
and 3D), whereas in CV07-270, the heavy chain dominates as frequently found in other antibodies 
.CC-BY-NC 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 16, 2020. . https://doi.org/10.1101/2020.08.15.252320doi: bioRxiv preprint 
9 
 
(Fig. 3B and 3E). Upon interaction with the RBD, CV07-250 has a buried surface area (BSA) of 399 
Å2 and 559 Å2 on the heavy and light chains, respectively, compared to 714 Å2 and 111 Å2 in CV07-
270. CV07-250 uses CDR H1, H3, L1, L3, and framework region 3 (LFR3) for RBD interaction (Fig. 
3D and Fig. 4A, 4B and 4C), whereas CV07-270 interacts with CDR H1, H3, L1, and L2 (Fig. 3E and 
Fig. 4D, 4E and 4F).  
The epitope of CV07-250 completely overlaps with the ACE2 binding site with a similar angle of 
approach as ACE2 (Fig. 3A, 3C, 4G and 4I). In contrast, the CV07-270 epitope only partially overlaps 
with the ACE2 binding site and the antibody approaches the RBD from a different angle compared to 
CV07-250 and ACE2 (Fig. 3B, 3C, 4H, 4I), explaining differences in ACE2 competition. Although 
CV07-250 and CV07-270 both contact 25 epitope residues, only seven residues are shared 
(G446/G447/E484/G485/Q493/S494/Q498). Furthermore, CV07-270 binds to a similar epitope as 
SARS-CoV-2 neutralizing antibody P2B-2F6 (Ju et al., 2020) with a similar angle of approach (Fig. 
S9). In fact, 18 out of 20 residues in the P2B-2F6 epitope overlap with the CV07-270 epitope, 
although CV07-270 and P2B-2F6 are encoded by different germline genes for both heavy and light 
chains.  
Interestingly, CV07-250 was isolated 19 days after symptom onset, but already acquired 33 SHM, the 
highest number among all S1+ MBCs (Fig. S2C). Some non-germline amino acids are not directly 
involved in RBD binding, including all five SHMs on CDR H2 (Fig. S10). This observation suggests 
that CV07-250 could have been initially affinity-matured against a different antigen. 
 
Prophylactic and therapeutic mAbs in a COVID-19 animal model 
Next, we selected mAb CV07-209 for evaluation of in vivo efficacy based on its high capacity to 
neutralize SARS-CoV-2 and the absence of reactivity to mammalian tissue. We used the hamster 
model of COVID-19, as it is characterized by rapid weight loss and severe lung pathology 
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(Osterrieder et al., 2020). In this experimental set-up, hamsters were intranasally infected with 
authentic SARS-CoV-2. Nine hamsters per group received either a prophylactic application of CV07-
209 24 hours before viral challenge, or a therapeutic application of CV07-209 or control antibody 
mGO53 two hours after viral challenge (Fig. 5A). 
Hamsters under control mAb treatment lost 5.5±4.4% (mean±SD) of body weight, whereas those that 
received mAb CV07-209 as a therapeutic or prophylactic single dose gained 2.2±3.4% or 4.8±3.4% 
weight after 5 days post-infection (dpi), respectively. Mean body weights gradually converged in the 
animals followed up until 13 dpi, reflecting the recovery of control-treated hamsters from SARS-CoV-2 
infection (Fig. 5B). 
To investigate the presence of SARS-CoV-2 in the lungs, we measured functional SARS-CoV-2 
particles from lung tissue homogenates. Plaque forming units were below the detection threshold for 
all animals in the prophylactic and in 2 of 3 in the treatment group at 3 and 5 dpi (Fig. 5C and 5D). 
qPCR measurements of lung viral genomic RNA copies revealed a 4-5 and 3-4 log decrease at both 
time points, indicating a dramatic reduction of SARS-CoV-2 virus particles in both the prophylactic 
and therapeutic group. However, genomic viral RNA copy numbers from nasal washes and laryngeal 
swaps were similar between all groups (Fig. 5C and 5D). 
Additionally, we performed histopathological analyses of infected hamsters. As expected, all lungs 
from control-treated animals sacrificed at 3 dpi revealed typical histopathological signs of necro-
suppurative pneumonia with suppurative bronchitis, necrosis of bronchial epithelial cells and 
endothelialitis (Fig. 6A). At 5 dpi, control-treated animals showed marked bronchial hyperplasia, 
severe interstitial pneumonia with marked type II alveolar epithelial cell hyperplasia and endothelialitis 
(Fig. 6D). In contrast, animals receiving prophylactic treatment with CV07-209 showed no signs of 
pneumonia, bronchitis, necrosis of bronchial epithelial cells, or endothelialitis at 3 dpi. A mild 
interstitial pneumonia with mild type II alveolar epithelial cell hyperplasia became apparent 5 dpi. 
Animals receiving therapeutic treatment with CV07-209 also showed a marked reduction of 
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histopathological signs of COVID-19 pathology, although at both time points one out of three animals 
showed mild bronchopulmonary pathology with signs of interstitial pneumonia and endothelialitis. 
These qualitative findings were mirrored in the reduction of the bronchitis and edema scores (Fig. 6B, 
6E and Supplementary Table ST7). 
To confirm the absence of viral particles under CV07-209 treatment, we performed in-situ 
hybridization of viral RNA at 3 dpi. No viral RNA was detectable in the prophylactic group, whereas all 
animals in the control group and one in the therapeutic group revealed intensive staining of viral RNA 
in proximity of bronchial epithelial cells (Fig. 6C). Taken together, these findings show that systemic 
application of SARS-CoV-2 neutralizing mAb CV07-209 protects hamsters from COVID-19 lung 
pathology and weight loss in both the prophylactic and the therapeutic setting.  
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Our results add several new aspects to the growing knowledge on the humoral immune response in 
SARS-CoV-2 infections. First, we solved the structures of two neutralizing mAbs binding to the RBD 
of SARS-CoV-2 at resolutions of 2.55 and 2.70 Å, allowing detailed characterization of the target 
epitopes and gaining insight into the mechanism of mAbs neutralizing SARS-CoV-2. SARS-CoV-2 
mAbs can compete with ACE2 binding and exert neutralizing activity by inhibiting viral particle binding 
to host cells (Barnes et al., 2020; Brouwer et al., 2020; Cao et al., 2020; Ju et al., 2020; Kreer et al., 
2020; Robbiani et al., 2020; Rogers et al., 2020; Wec et al., 2020), a key mechanism previously 
identified in SARS-CoV neutralizing antibodies (Prabakaran et al., 2006; ter Meulen et al., 2006). 
Steric hindrance of mAbs blocking ACE2 binding to the RBD provides one mechanistic explanation of 
virus neutralization (Barnes et al., 2020; Cao et al., 2020; Wu et al., 2020). CV07-250 clearly belongs 
to this category of antibodies, as its epitope lies within the ACE2 binding site and it approaches the 
RBD from a similar angle as ACE2. In contrast, the epitope of CV07-270 only partially overlaps with 
the ACE2 binding site and approaches the RBD ridge from a different angle. In line with these 
findings, competition of CV07-270 with ACE2 binding as detected by ELISA was very weak. Its 
mechanism of virus neutralization therefore remains elusive. Of note, there have been reports of 
neutralizing antibodies targeting epitopes distant to the ACE2 binding site (Chi et al., 2020). Future 
research will need to clarify if additional mechanisms like triggering conformational changes in the 
spike protein upon antibody binding contribute to virus neutralization, as reported for SARS-CoV 
(Walls et al., 2019). 
Secondly, the majority of our SARS-CoV-2 mAbs are close to germline configuration, supporting 
previous studies (Kreer et al., 2020; Robbiani et al., 2020). Given the increased probability of auto-
reactivity of near-germline antibodies, we examined reactivity with murine tissue and indeed found 
that a fraction of SARS-CoV-2 neutralizing antibodies also bound to with brain, lung, heart, kidney or 
gut expressed epitopes. Such reactivity with host antigens should ideally be prevented by 
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immunological tolerance mechanisms, but complete exclusion of such antibodies would generate 
“holes” in the antibody repertoire. In fact, HIV utilizes epitopes shared by its envelope and mammalian 
self-antigens, thus harnessing immunological tolerance to impair anti-HIV antibody responses (Yang 
et al., 2013) and impeding successful vaccination (Jardine et al., 2016). To defy viral escape in HIV, 
but similarly COVID-19, anergic strongly self-reactive B cells likely enter germinal centers and 
undergo clonal redemption to mutate away from self-reactivity, while retaining HIV or SARS-CoV-2 
binding (Reed et al., 2016). Interestingly, longitudinal analysis of mAbs in COVID-19 showed that the 
number of SHM in SARS-CoV-2-neutralizing antibodies only marginally increased over time (Kreer et 
al., 2020). This finding suggests that the self-reactivity observed in this study may not be limited to 
mAbs of the early humoral immune response in SARS-CoV-2 infections. Whether self-reactive 
antibodies could contribute to extra-pulmonary symptoms in COVID-19, awaits further studies and 
should be closely monitored also in vaccination trials.  
Finally, we evaluated in detail the in vivo efficacy of the most potent neutralizing antibody CV07-209 
in a Syrian hamster model. This model is characterized by a severe phenotype including weight loss 
and distinct lung pathology. Our results demonstrated that prophylaxis and treatment with a single 
dose of CV07-209 not only led to clinical improvement as shown by the absence of weight loss, but 
also to markedly reduced lung pathology. While the findings confirm the efficacy of prophylactic mAb 
administration reported by other groups in mice, hamsters and rhesus macaques (Cao et al., 2020; 
Liu et al., 2020; Rogers et al., 2020; Zost et al., 2020), our work is the first to demonstrate the efficacy 
of post-exposure treatment in hamsters leading to viral clearance, clinical remission and prevention of 
lung injury. To our knowledge, data on post-exposure treatment so far were restricted to transgenic 
hACE2 mice (Cao et al., 2020) and a mouse model using adenovector delivery of human ACE2 
before viral challenge (Liu et al., 2020). Collectively, our results indicate that mAb treatment can be 
fine-tuned for exclusion of self-reactivity with mammalian tissues and that mAb administration can 
also be efficacious after the infection, which will be the prevailing setting in COVID-19 patients. 
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Fig.1 | Identification and characterization of potent SARS-CoV-2 neutralizing mAbs. 
(A) Diagram depicting the strategy for isolation of 18 potently neutralizing mAbs (Top-18). (B) Normalized binding to S1 of SARS-CoV-2 for 
mAbs isolated from antibody secreting cells (▼; blue = S1-binding, grey = not S1-binding). (OD=optical density in ELISA) (C) Normalized 
binding to S1 of SARS-CoV-2 for mAbs isolated from S1-stained memory B cells (▲; colors like in (B)) (D) S1-binding plotted against the 
number of somatic hypermutations (SHM) for all S1-reactive mAbs.  
(E) Concentration-dependent binding of Top-18 SARS-CoV-2 mAbs to the RBD of S1 (mean±SD from two wells of one experiment). (F) 
Concentration-dependent neutralization of authentic SARS-CoV-2 plaque formation by Top-18 mAbs (mean±SD from two independent 
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Fig. 2 | SARS-CoV-2 neutralizing antibodies can bind to murine tissue. 
Immunofluorescence staining of SARS-CoV-2 mAbs (green) on murine organ sections showed specific binding to distinct anatomical 
structures, including (A) staining of hippocampal neuropil with CV07-200 (cell nuclei depicted in blue), 
(B) staining of bronchial walls with CV07-222, (C) staining of vascular walls with CV07-255, and 
(D) staining of intestinal walls with CV07-270. Smooth muscle tissue in (B-D) was co-stained with a commercial smooth muscle actin 
antibody (red).  
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Fig. 3 | Crystal structures of mAbs in complex with SARS-CoV-2 RBD. 
(A) CV07-250 (cyan) in complex with RBD (white). (B) CV07-270 (pink) in complex with RBD (white). (C) Human ACE2 with SARS-CoV-2 
RBD (PDB 6M0J) (Lan et al., 2020). (D-E) Epitopes of (D) CV07-250 and (E) CV07-270. Epitope residues contacting the heavy chain are in 
orange and the light chain in yellow. CDR loops and framework region that contact the RBD are labeled. (F) ACE2-binding residues on the 
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Fig. 4 | Interactions and angle of approach at the RBD-antibody interface. 
(A-C) Key interactions between CV07-250 (cyan) and RBD (white) are highlighted. (A) CDR H3 of CV07-250 forms a hydrogen-bond 
network with RBD Y489 and N487. (B) VH Y100b (CDR H3), VL F32 (CDR L1), and VL Y91 (CDR L3) of CV07-250 form a hydrophobic 
aromatic patch for interaction with RBD L455 and F456. (C) The side chain of VL S67 and backbone amide of VL G68 from FR3 is engaged 
in a hydrogen-bond network with RBD G446 and Y449. (D-F) Interactions between CV07-270 (cyan) and RBD (white) are illustrated. (D) 
Residues in CDR H1 of CV07-270 participate in an electrostatic and hydrogen-bond network with RBD R346 and K444. (E) VH W100h and 
VH W100k on CDR H3 of CV07-270 make π-π stacking interactions with Y449. VH W100k is also stabilized by a π-π stacking interaction 
with VL Y49. (F) VH R100g on CDR H3 of CV07-270 forms an electrostatic interaction with RBD E484 as well as a π-cation interaction with 
RBD F490. Oxygen atoms are in red, and nitrogen atoms in blue. Hydrogen bonds are represented by dashed lines. (G-I) Zoomed-in views 
of the different RBD ridge interactions with (G) CV07-250, (H) CV07-270, and (I) ACE2 (PDB 6M0J) (Lan et al., 2020). The ACE2-binding 
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Fig. 5 | Prophylactic and therapeutic application of mAb CV07-209 in a COVID-19 hamster model. 
(A) Schematic overview of the animal experiment. (B) Body weight of hamsters after virus challenge and prophylactic (pink) or therapeutic 
(blue) application of SARS-CoV-2 neutralizing mAb CV07-209 or control antibody (mean±SEM from n=9 animals per group from day -1 to 3, 
n=6 from days 4 to 5;  n=3 from days 6 to 13; mixed-effects model with posthoc Dunnett’s multiple tests in comparison to control group; 
significance levels shown as * (p<0.05), ** (p<0.01), *** (p<0.001), **** (p<0.0001), or not shown when not significant). (C-D) Quantification 
of plaque forming units (PFU) from lung homogenates and quantification of SARS-CoV-2 RNA copies per 105 cellular transcripts from 
samples and timepoints as indicated. PFU were set to 5 when not detected, RNA copies below 1 were set to 1. Bars indicate mean. Dotted 
lines represent detection threshold. 
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Fig. 6 | Histopathological analysis of hamsters after SARS-CoV-2 infection. 
(A) Histopathology of representative haematoxylin and eosin stained, paraffin-embedded bronchi with inserted epithelium (upper row) and 
lung parenchyma with inserted blood vessels (lower row) at 3 dpi. Severe suppurative bronchitis with immune cell infiltration (hash) is 
apparent only in the control-treated animals with necrosis of bronchial epithelial cells (diagonal arrows). Necro-suppurative interstitial 
pneumonia (upward arrows) with endothelialitis (downward arrows) is prominent in control-treated animals. Scale bars: 200 µm in bronchus 
overview, 50 µm in all others. (B) Bronchitis and edema score at 3 dpi. (C) Detection of viral RNA (red) using in situ hybridization of 
representative bronchial epithelium present only in the control group. Scale bars: 50 µm. (D) Histopathology of representative lung sections 
from comparable areas as in (A) at 5 dpi. Staining of bronchi of control-treated animals showed a marked bronchial hyperplasia with 
hyperplasia of epithelial cells (diagonal arrow) and still existing bronchitis (hash), absent in all prophylactically treated and in 2/3 
therapeutically treated animals (upper row). Lung parenchyma staining of control-treated animals showed severe interstitial pneumonia with 
marked type II alveolar epithelial cell hyperplasia and endothelialitis (insets, downward arrows). Compared to control-treated animals, 
prophylactically treated animals showed only mild signs of interstitial pneumonia with mild type II alveolar epithelial cell hyperplasia (upward 
arrow), whereas  therapeutically treated animals showed a more heterogeneous picture with 1/3 showing no signs of lung pathology, 1/3 
animal showing only mild signs of interstitial pneumonia, and 1/3 animal showing a moderate multifocal interstitial pneumonia. Scale bars: 
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MATERIALS AND METHODS 
SARS-CoV-2-infected individuals and sample collection 
The patients have given written informed consent and analyses were approved by the Institutional 
Review Board of Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, 
Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin. All patients in this study were tested 
positive for SARS-CoV-2 infection by RT-PCR. Patient characteristics are described in 
Supplementary Table ST1. 
 
PBMC collection and FACS staining 
Recombinant SARS-CoV-2-S1 protein produced in HEK cells (Creative Diagnostics, DAGC091) was 
covalently labeled using CruzFluor647 (Santa Cruz Biotechnology, sc-362620) according to the 
manufacturer’s instructions. 
Using fluorescence-activated cell sorting we sorted viable single cells from freshly isolated peripheral 
blood mononuclear cells (PBMCs as 7AAD-CD19+CD27+CD38+ antibody-secreting cells (ASCs) or 
SARS-CoV2-S1-enriched 7AAD-CD19+CD27+ memory B cells (MBCs) into 96-well PCR plates. 
Staining was performed on ice for 25 minutes in PBS with 2 % FCS using the following antibodies: 7-
AAD 1:400 (Thermo Fisher Scientific), CD19-BV786 1:20 (clone SJ25C1, BD Biosciences, 563326), 
CD27-PE 1:5 (clone M-T271, BD Biosciences, 555441), CD38-FITC 1:5 (clone HIT2, BD 
Biosciences, 560982), and SARS-CoV-S1-CF647 at 1 µg/ml for patients CV07, CV38, CV23, CV24, 
CV 38, CV48, CV-X1, CV-X2 and CV01 (second time point, fig. S1). The first patients (CV01 (first 
time point), CV03, and CV05) were stained with a divergent set of antibodies: CD19-PE 1:50 (clone 
HIB19, BioLegend, 302207), CD38-PEcy7 1:50 (clone HIT2, BioLegend, 303505), CD27-APC 1:50 
(clone O323, BioLegend, 302809) and DAPI as viability dye. 
 
Generation of recombinant human monoclonal antibodies 
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Monoclonal antibodies were generated following our established protocols (Kornau et al., 2020; Kreye 
et al., 2016) with modifications as mentioned. We used a nested PCR strategy to amplify variable 
domains of immunoglobulin heavy and light chain genes from single cell cDNA and analyzed 
sequences with aBASE module of customized Brain Antibody Sequence Evaluation (BASE) software 
(Reincke et al., 2019). Pairs of functional Ig genes were PCR-amplified using specific primers with Q5 
Polymerase (NEB). PCR-product and linearized vector were assembled using Gibson cloning with 
HiFi DNA Assembly Master Mix (NEB). Cloning was considered successful when sequence identify 
>99.5% was given, verified by the cBASE module of BASE software. For mAb expression, human 
embryonic kidney cells (HEK293T) were transiently transfected with matching Ig heavy and light 
chains. Three days later mAb containing cell culture supernatant was harvested. Ig concentrations 
were determined and used for reactivity and neutralization screening, if Ig concentration was above 1 
µg/ml. For biophysical characterization assays and in vivo experiments, supernatants were purified 
using Protein G Sepharose beads (GE Healthcare), dialyzed against PBS and sterile-filtered using 
0.2 µm filter units (GE Healthcare). For in vivo experiments, mAbs were concentrated using Pierce™ 
3K Protein Concentrator PES (Thermo Scientific). 
 
SARS-CoV-2-S1 ELISA 
Screening for SARS-CoV-2-specific mAbs was done by using anti-SARS-CoV-2-S1 IgG ELISAs 
(EUROIMMUN Medizinische Labordiagnostika AG) according to the manufacturer’s protocol. mAb 
containing cell culture supernatants were pre-diluted 1:5, patient sera 1:100. Optical density (OD) 
ratios were calculated by dividing the OD at 450 nm by the OD of the calibrator included in the kit. OD 
ratios of 0.5 were considered reactive. 
 
RBD ELISA 
Binding to the receptor-binding domain (RBD) of S1 was tested in an ELISA. To this end, a fusion 
protein (RBD-Fc) of the signal peptide of the NMDA receptor subunit GluN1, the RBD-SD1 part of 
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SARS-CoV2-S1 (amino acids 319-591) and the constant region of rabbit IgG1 heavy chain (Fc) was 
expressed in HEK293T cells and immobilized onto 96-well plates from cell culture supernatant via 
anti-rabbit IgG (Dianova, 111-035-045) antibodies. Then, human mAbs were applied and detected 
using horseradish peroxidase (HRP)-conjugated anti-human IgG (Dianova, 109-035-088) and the 
HRP substrate 1-step Ultra TMB (Thermo Fisher Scientific, Waltham, MA). All S1+ mAbs were 
screened at a human IgG concentration of 10 ng/ml to detect strong RBD binders and the ones 
negative at this concentration were re-evaluated for RBD reactivity using a 1:5 dilution of the cell 
culture supernatants. To test for specificity within the coronavirus family, we expressed and 
immobilized Fc fusion proteins of the RBD-SD1 regions of MERS-CoV, SARS-CoV and the endemic 
human coronaviruses HCoV-229-E, HCoV-NL63, HCoV-HKU1, and HCoV-229E and applied mAbs at 
1 µg/ml. The presence of immobilized antigens was confirmed by incubation with HRP-conjugated 
anti-rabbit IgG (Dianova). Assays for concentration-dependent RBD binding (Fig. 1E) were developed 
using 1-step Slow TMB (Thermo Fisher Scientific). EC50 was determined from non-linear regression 
models using Graph Pad Prism 8. 
To evaluate the ability of mAbs to interfere with the binding of ACE2 to SARS-CoV-2 RBD, we 
expressed ACE2-HA, a fusion protein of the extracellular region of human ACE2 (amino acids 1-615) 
followed by a His-tag and a hemagglutinin (HA)-tag in HEK293T cells and applied it in a modified 
RBD-ELISA. Captured RBD-Fc was incubated with mAbs at 0.5 µg/ml for 15 minutes and 
subsequently with ACE2-HA-containing cell culture supernatant for 1 h. ACE2-HA binding was 
detected using anti-HA antibody HA.11 (clone 16B12, BioLegend, San Diego, CA, MMS-101P), HRP-
conjugated anti-mouse IgG (Dianova, 115-035-146) and 1-step UltraTMB. 
For experiments regarding the competition between mAbs for RBD binding, purified monoclonal 
antibodies were biotinylated using EZ-Link Sulfo-NHS-Biotin (Thermo Fisher) according to the 
manufacturer’s instructions. Briefly, 50-200 µg of purified antibody were incubated with 200-fold molar 
excess Sulfo-NHS-Biotin for 30 minutes at room temperature. Excess Sulfo-NHS-Biotin was removed 
by dialysis for 16 hours. Recovery rate of IgG ranged from 60-100%. RBD-Fc captured on ELISA 
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plates was incubated with mAbs at 10 µg/ml for 15 minutes. Then, one volume of biotinylated mcAbs 
at 100 ng/ml was added and the mixture incubated for additional 15 minutes, followed by detection 
using HRP-conjugated streptavidin (Roche Diagnostics) and 1-step Ultra TMB. Background by the 
HRP-conjugated detection antibodies alone was subtracted from all absorbance values. 
 
Circos plot of public clonotypes 
Antibodies which share same V and J gene on both Ig heavy and light chain are considered to be one 
clonotype. Such clonotypes are considered public if they are identified in different patients. After 
identification of public clonotypes, they were plotted in a Circos plot using the R package circlize (Gu 
et al., 2014). 
 
Identification of 18 strongly neutralizing antibodies 
To identify the most potent SARS-CoV-2 neutralizing mAb, all 122 S1-reactive mAbs were screened 
for binding to RBD. 86 were defined as strongly binding to RBD (defined as detectable binding at 10 
ng/ml in an RBD ELISA) and then assessed for neutralization of authentic SARS-CoV-2 at 25 and 
250 ng/ml using mAb-containing cell culture supernatants. Antibodies were further selected (i) as the 
strongest neutralizing mAb of the respective donor and / or (ii) with an estimated IC50 of 25 ng/ml or 
below and / or (iii) with an estimated IC90 of 250 ng/ml or below. These were defined as the 18 most 
potent antibodies (Top-18) and expressed as purified antibodies for detailed biophysical 
characterization. 
 
Surface plasmon resonance measurements 
The antigen (SARS-CoV-2 S protein-RBD-mFc, Accrobiosystems) was reversibly immobilized on a 
C1 sensor chip via anti-mouse IgG. Purified mAbs were injected at different concentrations in a buffer 
consisting of 10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.05% Tween 20. CV-X1-126 and 
CV38-139 were analyzed in a buffer containing 400 mM NaCl as there was a slight upward drift at the 
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beginning of the dissociation phase due to non-specific binding of to the reference flow. Multi-cycle-
kinetics analyses were performed in duplicates except for non-neutralizing CV03-191. Ka, Kd and KD-
values were determined using a monovalent analyte model. Recordings were performed on a Biacore 
T200 instrument at 25°C. 
 
Plaque reduction neutralization test 
To detect neutralizing activity of SARS-CoV-2-specific mAbs, plaque reduction neutralization tests 
(PRNT) were done as described before (Wolfel et al., 2020). Briefly, Vero E6 cells (1.6 x105 cells/well) 
were seeded in 24-well plates and incubated overnight. For each dilution step, mAbs were diluted in 
OptiPro and mixed 1:1 with 200 μl virus (Munich isolate 984) (Wolfel et al., 2020) solution containing 
100 plaque forming units. The 400 μl mAb-virus solution was vortexed gently and incubated at 37°C 
for 1 hour. Each 24-well was incubated with 200 μl mAb-virus solution. After 1 hour at 37°, the 
supernatants were discarded and cells were washed once with PBS and supplemented with 1.2% 
Avicel solution in DMEM. After 3 days at 37°C, the supernatants were removed and the 24-well plates 
were fixed and inactivated using a 6% formaldehyde/PBS solution and stained with crystal violet. All 
dilutions were tested in duplicates. For PRNT-screening mAb dilutions of 25 and 250 ng of IgG/ml 
were assessed. IC50 was determined from non-linear regression models using Graph Pad Prism 8. 
 
Immunocytochemistry 
Recombinant spike protein-based immunofluorescence assays were done as previously described 
(Buchholz et al., 2013; Corman et al., 2020; Wolfel et al., 2020). Briefly, VeroB4 cells were 
transfected with previously described pCG1 plasmids encoding SARS-CoV-2, MERS-CoV, HCoV-
NL63, -229E, -OC43, and -HKU1 spike proteins (Buchholz et al., 2013). For transfection, Fugene HD 
(Roche) was used in a Fugene to DNA ratio of 3:1. After 24 hours, transfected as well as 
untransfected VeroB4 cells were harvested and resuspended in DMEM/10% FCS to achieve a cell 
density of 2.5x105 cells/ml each. Transfected and untransfected VeroB4 cells were mixed 1:1 and 50 
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μl of the cell suspension was applied to each incubation field of a multitest cover slide (Dunn 
Labortechnik). The multitest cover slides were incubated for 6 hours before they were washed with 
PBS and fixed with ice-cold acetone/methanol (ratio 1:1) for 10 minutes. For the immunofluorescence 
test, the incubation fields were blocked with 5% non-fat dry milk in PBS/0.2% Tween for 60 minutes. 
Purified mAbs were diluted in EUROIMMUN sample buffer to a concentration of 5 µg/ml and 30 μl of 
the dilution was applied per incubation field. After 1 hour at room temperature, cover slides were 
washed 3 times for 5 minutes with PBS/0.2% Tween. Secondary detection was done using a 1:200 
dilution of a goat-anti human IgG-Alexa488 (Dianova). After 30 minutes at room temperature, slides 
were washed 3 times for 5 minutes and rinsed with water. Slides were mounted using DAPI 
prolonged mounting medium (FisherScientific). 
 
Crystal structure determination of Fab-RBD complexes 
The receptor binding domain (RBD; residues 319-541) of the SARS-CoV-2 spike (S) protein was 
expressed in High Five cells and purified using affinity and size exclusion chromatography as 
described previously (Yuan et al., 2020b). Residues in the elbow region of CV07-250 
(112SSASTKG118) were mutated to 112FNQIKP117 to reduce elbow flexibility and facilitate crystal 
packing (Bailey et al., 2018). CV07-250 and CV07-270 Fabs were expressed in ExpiCHO cells and 
purified using affinity and size exclusion chromatography. The Fab/RBD complexes were formed by 
mixing the two components in an equimolar ratio and incubating overnight at 4°C before setting-up 
crystal trials. The complexes of CV07-250/RBD and CV07-270/RBD were screened for crystallization 
at 20.0 and 12.0 mg/ml, respectively, using 384 conditions of the JCSG Core Suite (Qiagen) on our 
robotic CrystalMation system (Rigaku) at The Scripps Research Institute. Crystals appeared after day 
3, were harvested after day 7, and then flash-cooled in liquid nitrogen for X-ray diffraction 
experiments. Diffraction data were collected at cryogenic temperature (100 K) at Stanford 
Synchrotron Radiation Lightsource (SSRL) on the newly constructed Scripps/Stanford beamline 12-1 
with a beam wavelength of 0.97946 Å and processed with HKL3000 (Minor et al., 2006). Diffraction 
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data were collected from crystals grown in conditions: 0.085 M HEPES pH 7.5, 10% (v/v) ethylene 
glycol, 15% (v/v) glycerol, 8.5% (v/v) 2-propanol, 17% (w/v) polyethylene glycol 4000 for the CV07-
250/RBD complex and 0.1 M sodium cacodylate pH 6.5, 0.2 M sodium chloride, 2 M ammonium 
sulfate, 15% (v/v) ethylene glycol for the CV07-270/RBD complex. The X-ray structures were solved 
by molecular replacement (MR) using PHASER (McCoy et al., 2007) with MR models for the RBD 
and CV07-270 Fab from PDB 6W41 (Yuan et al., 2020b) and 4FQH, respectively. The MR model for 
CV07-250 Fab was generated using Repertoire Builder (Schritt et al., 2019). Iterative model building 
and refinement were carried out in COOT (Emsley and Cowtan, 2004) and PHENIX (Adams et al., 
2010), respectively. In the CV07-250 + RBD structure, residues 319-337, 357- 366, 371-374, 383- 
396, 516-541 were not modeled due to paucity of electron density. The N and C terminal regions are 
normally disordered in the SARS CoV-2 RBD structures. These flexible regions are not involved in 
any other contacts, including crystal lattice contacts, and are on the opposite side of the RBD to the 
epitope, which is well ordered. In the CV07-270 + RBD structure, Fab residues in a region of the 
heavy-chain constant domain also have greater mobility as commonly found in Fabs. Likewise, the N 
and C- terminal residues of 319-333 and 528-541 in both RBD molecules of the asymmetric unit are 
disordered. Epitope and paratope residues, as well as their interactions, were identified by accessing 
PDBePISA at the European Bioinformatics Institute (https://www.ebi.ac.uk/pdbe/prot_int/pistart.html). 
 
Murine tissue reactivity screening 
Preparations of brain, lung, heart, liver, kidney and gut from 8-12 weeks old C57BL/6J mice were 
frozen in -50°C 2-methylbutane, cut on a cryostat in 20 µm sections and mounted on glass slides. For 
tissue reactivity screening according to established protocols (Kreye 2016 Brain), thawed unfixed 
tissue slices were rinsed with PBS then blocked with blocking solution (PBS supplemented with 2% 
Bovine Serum Albumin (Roth) and 5% Normal Goat Serum (Abcam)) for 1 hour at room temperature 
before incubation of mAbs at 5 µg/ml overnight at 4°C. After three PBS washing steps, goat anti-
human IgG-Alexa Fluor 488 (Dianova, 109-545-003) diluted in blocking solution was applied for 2 
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hours at room temperature before additional three washes and mounting using DAPI-containing 
Fluoroshield. Staining was examined under an inverted fluorescence microscope (Olympus CKX41, 
Leica DMI6000) or confocal device (Leica TCS SL). For co-staining, tissue was processed as above, 
but sections were fixed with 4% PFA in PBS for 10 minutes at room temperature before blocking. For 
co-staining, the following antibodies were used: mouse Smooth Muscle Actin (clone 1A4, Agilent, 172 
003), goat anti-mouse IgG-Alexa Fluor 594 (Dianova, 115-585-003). For nuclei staining DRAQ5™ 
(abcam, ab108410) was used. 
 
HEp2 cell assay 
HEp-2 cell reactivity was investigated using the NOVA Lite HEp-2 ANA Kit (Inova Diagnostics) 
according to the manufacturer’s instructions using mAb containing culture supernatant (screening of 
all S1+ mAbs) or purified mAbs at 50 µg/ml (polyreactivity testing of CV07-200, CV07-209, CV07-222, 
CV07-255, CV07-270 and CV38-148) and examined under an inverted fluorescence microscope. 
 
Polyreactivity screening ELISA 
Purified mAbs were screened for reactivity against cardiolipin and beta-2 microglobulin at 50 µg/ml 
using routine laboratory ELISAs kindly performed by Christian Meisel (Labor Berlin).  
 
Hamster model of SARS-CoV-2 infection 
The animal experiment was approved by the Landesamt für Gesundheit und Soziales in Berlin, 
Germany (approval number 0086/20) and performed in compliance with relevant national and 
international guidelines for care and humane use of animals. In vitro and animal work was conducted 
under appropriate biosafety precautions in a BSL-3 facility at the Institute of Virology, Freie 
Universität Berlin, Germany. Twenty-seven six-week old female and male golden Syrian hamsters 
(Mesocricetus auratus; outbred hamster strain RjHan:AURA, Janvier Labs) were kept in groups of 3 
animals in enriched, individually ventilated cages. The animals had ad libitum access to food and 
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water and were allowed to acclimate to these conditions for seven days prior to prophylactic 
treatment and infection. Cage temperatures and relative humidity were recorded daily and ranged 
from 22-24°C and 40-55%, respectively. 
Virus stocks for animal experiments were prepared from the previously published SARS-CoV-2 
München isolate (Wolfel et al., 2020). Viruses were propagated on Vero E6 cells (ATCC CRL-1586) 
in minimal essential medium (MEM; PAN Biotech) supplemented with 10% fetal bovine serum (PAN 
Biotech) 100 IU/ml Penicillin G and 100 µg/ml Streptomycin (Carl Roth). Stocks were stored at -80°C 
prior to experimental infections. 
For the SARS-CoV-2 challenge experiments, hamsters were randomly distributed into three groups: 
In the first group (prophylaxis group), animals received an intraperitoneal (i.p.) injection of 18 mg per 
kg bodyweight of SARS-CoV-2 neutralizing mAb CV07-209 24 hours prior to infection. In the second 
and third group (treatment and control group, respectively), animals were given the identical mAb 
amount two hours after infection, either with 18 mg/kg of CV07-209 (treatment group) or with 20 
mg/kg of non-reactive isotype-matched mGO53 (control group). Hamsters were infected intranasally 
with SARS-CoV-2 infected as previously described (Osterrieder et al., 2020). 
On days 2, 5 and 13 post infection, three hamsters of each group were euthanized by exsanguination 
under general anesthesia as described (Nakamura et al., 2017). Nasal washes, tracheal swabs, and 
lungs (left and right) were collected for histopathological examinations and/or virus titrations and RT-
qPCR. Body weights were recorded daily and clinical signs of all animals were monitored twice daily 
throughout the experiment. 
 
 
Histopathology and in situ hybridization 
For histopathological examination and in situ hybridization (ISH) of lung tissues, the left lung lobe was 
carefully removed and immersed in fixative solution (4% formalin, pH 7.0) for 48 hours. Lungs were 
then embedded in paraffin and cut in 2 μm sections. For histopathology, slides were stained with 
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hematoxylin and eosin (HE) followed by blinded microscopic evaluation by board‐certified veterinary 
pathologists as previously described (Dietert et al., 2017; Osterrieder et al., 2020). The following 
parameters were evaluated to assess three different scores: (1) the bronchitis score that includes 
severity of bronchial inflammation and epithelial cell necrosis of bronchi; (2) the regeneration score 
combining the presence of hyperplasia of bronchial epithelial cells and alveolar type II epithelial cells; 
and (3) the edema score including alveolar and perivascular edema. 
ISH was performed as reported previously (Erickson et al., 2020; Osterrieder et al., 2020) using the 
ViewRNA™ ISH Tissue Assay Kit (Invitrogen by Thermo Fisher Scientific) following the 
manufacturer's instructions with minor adjustments. Probes for the detection of the Nucleoprotein (N) 
gene RNA of SARS-CoV-2 (NCBI database NC_045512.2, nucleotides 28,274 to 9,533, assay ID: 
VPNKRHM), and the murine housekeeping gene eukaryotic translation elongation factor-1α (EF1a; 
assay ID: VB1-14428-VT, Affymetrix, Inc.), that shares 95% sequence identity with the Syrian 
hamster, were designed. Lung sections (2 µm thickness) on adhesive glass slides were dewaxed in 
xylol and dehydrated in ethanol. Tissues were incubated at 95°C for 10 minutes with subsequent 
protease digestion for 20 minutes. Sections were fixed with 4% paraformaldehyde in PBS (Alfa Aesar, 
Thermo Fisher) and hybridized with the probes. Amplifier and label probe hybridizations were 
performed according to the manufacturer's instructions using fast red as the chromogen, followed by 
counterstaining with hematoxylin for 45 s, washing in tap water for 5 minutes, and mounting with 
Roti®-Mount Fluor-Care DAPI (4, 6-diaminidino-2-phenylindole; Carl Roth). An irrelevant probe for 
the detection of pneumolysin was used as a control for sequence-specific binding. HE-stained and 
ISH slides were analyzed and images taken using a BX41 microscope (Olympus) with a DP80 
Microscope Digital Camera and the cellSens™ Imaging Software, Version 1.18 (Olympus). 
 
Virus titrations, RNA extractions and RT-qPCR 
To determine virus titers from 25 mg lung tissue, tissue homogenates were serially diluted and titrated 
on Vero E6 cells in 12-well-plates. Three days later, cells were formalin-fixed, stained with crystal 
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violet and plaques were counted. RNA was extracted from homogenized lungs, nasal washes and 
tracheal swabs using the innuPrep Virus DNA/RNA Kit (Analytik Jena) according to the 
manufacturer’s instructions. We quantified RNA using a one-step RT qPCR reaction with the NEB 
Luna Universal Probe One-Step RT-qPCR kit (New England Biolabs) and previously published 
TaqMan primers and probes (SARS-CoV-2 E_Sarbeco and hamster RPL18) (Corman et al., 2020; 
Zivcec et al., 2011) on a StepOnePlus RealTime PCR System (Thermo Fisher Scientific). 
 
Statistical Analysis 
All statistical tests were performed using GraphPad Prism, version 8.4. For comparison of SHM 
number, ordinary one-way ANOVA tests with posthoc Tukey's multiple comparisons tests were used. 
Statistical significance of bodyweight changes from hamster experiments was tested using a mixed-
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Fig. S1 | SARS-CoV-2-S1 serum IgG response from COVID-19 patients. 
Serum IgG response determined as the normalized optical density (OD) in a SARS-CoV-2-S1 ELISA in relation to the time point of 
diagnosis defined by the first positive qPCR test. Upward arrowhead denotes the appearance of first symptoms. Downward arrowhead 
denotes the PBMC isolation. From patient CV01, PBMC samples were isolated at two time points as indicted by the second downward 



















































































.CC-BY-NC 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a












Fig. S2 | Flow cytometry gating and characteristics of immunoglobulin sequences. 
(A-B) A representative flow cytometry plot from patient CV38 indicating gating on (A) CD19+CD27+antibody-secreting cells (ASC) and (B) 
SARS-CoV-2-S1-stained memory B cells (S1-MBC). Cells were pre-gated on live CD19+ B cells. (C) Comparison of somatic hypermutation 
(SHM) count within immunoglobulin V genes combined from heavy and light chains of S1-reactive (S1+, blue) and non-S1-reactive (S1-, 
grey) mAbs. Statistical significance was determined using a one-way ANOVA (F = 19.22) with posthoc Tukey's multiple comparisons tests. 
(ASC: n = 20 S1+, n = 260 S1-; S1-MBC: n = 102 S1+, n = 50 S1-). All expressed mAbs are displayed. Each triangle represents a S1+ 
(blue) or S1- (grey) mAb, isolated from an ASC (pointing downwards) or a S1-MBC (pointing upwards). (D-E) Length comparison of 
complementarity-determining region (CDR) 3 amino acid sequences between S1+ and S1- mAbs within (D) heavy and (E) light chains. 
Symbols and colors have the same meaning as in (C). (F) Frequency of RBD-binder (S1+RBD+) and non-RBD-binder (S1+RBD-) relative 
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Fig. S3. | Comparison of variable gene usage. 
Comparison of gene usage between SARS-CoV-2-S1-reactive (S1+) and non-reactive (S1-) mAbs is shown for immunoglobulin (A) variable 
heavy (IGHV), (B) variable kappa (IGKV) and (C) variable lambda (IGLV) genes. Bars depict percentage of gene usage of all expressed 
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Fig. S4 | Clonal expansion and public clonotypes. 
(A) Pie charts represent clonal relationship of all expressed mAbs from each donor separately for antibody secreting cells (ASC) and S1-
stained memory B cells (S1-MBC). mAbs were considered S1-reactive (S1+) or non-S1-reactive (S1-) based on SARS-CoV-2-S1 ELISA 
measurements. Antibodies were considered to be clonally expanded when they were isolated from multiple cells. (B) Circos plot displays all 
isolated mAbs from ten donors. Interconnecting lines indicate relationship between mAbs that share the same V and J gene on both Ig 
heavy and light chain. Such public or shared clonotypes in which more than 50% of mAbs are S1-reactive are represented as colored lines. 
Small black angles at the outer circle border indicate expanded clones within the respective donor. (C) Properties of public clonotypes from 
 
Patient mAb Reactivity IGHV IGHJ CDR H3 IGKV/ 
IGLV 
IGKJ/ 
IGLJ CDR L3 
 CV07 HL CV07-255 RBD 1-2*02 4*02 ARDSRFSYVNGEFDY 2-23*02 3*02 CSYAGHSTWV 
 CV23 HL CV23-121 S1- 1-2*02 4*02 ARELGSWDGRFDY 2-23*02 3*02 CSYAGSSTWV 
 CV38 HL CV38-186 RBD 1-2*02 4*02 ARDQSPDILKSPFDY 2-23*03 3*02 CSYAGSSTFG 
 CV03 HK CV03-191 RBD 3-11*06 4*02 ARDLGYNRRFDY 1-33*01 4*01 QQYDNLPLT 
 CV07 HK CV07-209 RBD 3-11*01 4*02 ARDGVIPPRFDY 1-33*01 4*01 QQYDNLPLT 
 CV-X1 HK CV-X1-143 RBD 3-11*05 4*02 ARDLGYSTRFDY 1-33*01 4*01 QQYDNLPLT 
 CV01 HL CV01-273 RBD 4-4*02 4*02 ARGWGKGPPLGY 2-23*01 3*02 YSYAGSSTWV 
 CV38 HL CV38-119 RBD 4-4*02 4*02 ARAWNFDY 2-23*01 3*02 CSYAGSSNWV 
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S1+ mAbs according to the colors used in (B) with sequence similarities between mAbs isolated from different donors, also within 
complementarity-determining region (CDR) three. IGHV, IGHJ IGKV, IGKJ, IGLV, IGLJ = V and J genes of immunoglobulin heavy, kappa, 
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Fig. S5 | Binding kinetic measurements of mAbs to RBD. 
Binding kinetics of mAbs to RBD were modeled (black) from multi-cycle surface plasmon resonance (SPR) measurements (blue, purple, 
orange). Fitted monovalent analyte model is shown. For CV07-200, neither a bivalent nor a monovalent analyte model described the data 
accurately (no model is shown). Three out of the 18 selected mAbs for detailed characterization (Top-18) were not analyzed using multi-
cycle-kinetics: CV07-270 was excluded as it interacted with the anti-mouse IgG reference surface on initial qualitative measurements. 
CV07-255 and CV-X2-106 were not analyzed since they showed biphasic binding kinetics and relatively fast dissociation rates in initial 
qualitative measurements. Non-neutralizing CV03-191, a mAb not included in the Top-18 mAbs, was included in the multicycle experiments 
as it has the same clonotype as strongly neutralizing CV07-209 (Fig. S4C). All measurements are performed by using a serial 2-fold dilution 
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Fig. S6 | Competition of mAbs for RBD binding with ACE2 and between SARS-CoV-2 mAbs. 
(A) ELISA-based measurements of human ACE2 binding to SARS-CoV-2 RBD after pre-incubation with the indicated neutralizing mAbs. 
Values are shown relative to antibody-free condition as mean+SD from three independent measurements. (B) Competition for RBD binding 
between combinations of potent neutralizing mAbs is illustrated as a heat map. Shades of green indicate the degree of competition for RBD 
binding of detection mAb in presence of 100-fold excess of competing mAb relative to non-competition conditions. Green squares indicate 
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Fig. S7 | Binding specificity of mAbs within coronaviruses.  
(A) Representative immunofluorescence staining on VeroB4 cells overexpressing spike protein of indicated coronavirus with SARS-CoV-2 
mAb CV07-209 at 5 µg/ml. For all other 17 of the selected 18 mAbs (Top-18, Supplementary Table ST4), similar results were obtained. (B) 
Binding of indicated mAbs to fusion proteins containing the RBD of indicated coronaviruses and the constant region of rabbit IgG revealed 












SARS2-CoV-2 MERS-CoV HCoV-HKU1 
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Fig. S8 | Representative staining on HEp-2 cells of selected S1-reactive antibodies. 
Representative HEp-2 cell staining with a commercial anti-nuclear antibody as positive control revealed nuclear binding (left). S1-reactive 
non-neutralizing mAb CV38-148 exhibited cytoplasmatic binding (middle). Neutralizing mAb CV07-209 showed no binding (right). All mAbs 
selected for detailed characterization (Top-18, Supplementary Table ST4) revealed similar results like CV07-209 when used at 50 µg/ml.  
  
Positive control CV38-148 CV07-209 
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Fig. S9 | Structural comparison of CV07-270/RBD and P2B-2F6/RBD complexes. 
(A) Structure of CV07-270 (pink) in complex with RBD (white). (B) Structure of P2B-2F6 (blue) in complex with RBD (white) (PDB 7BWJ) 
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Fig. S10 | Comparison of sequences of CV07-250 and CV07-270 to their putative germline sequences. 
(A) Alignment of CV07-250 with the germline IGHV1-18 sequence (nucleotide SHM rate 5.8%) and IGLV2-8 (nucleotide SHM rate 5.4%).  
(B) Somatic mutations VH S31H, VL G29A, VL N31H, VL Y32F, VL S34T, and VL L46V are located in the CV07-250 paratope with other 
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somatic mutations in all of the CDRs that may affect overall CDR conformation and interactions. Hydrogen bonds are represented by 
dashed lines. Distances between atoms are shown in solid lines. CV07-250 heavy chain is in dark cyan and light chain is in light cyan. 
SARS-CoV-2 RBD is in light grey. (C) Alignment of CV07-270 with the germline IGHV3-11 sequence (nucleotide SHM rate 0.7%) and 
IGLV2-14 (nucleotide SHM rate 0%). The regions that correspond to CDR H1, H2, H3, L1, L2, and L3 are indicated. Residues that differ 
from the germline are highlighted in red. Residues that interact with the RBD are highlighted in yellow. Residue positions in the CDRs are 
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Supplementary Table ST1 | Description of patient cohort.  
General 


































CVD CVD N N N 









































































13 / 13 10 / 11 3 / 13 5 / 6 0 / 0 7 / 8 6 / 14 10 / 9 11 / 12 2 / - 
SARS-CoV-2 
serum IgG at 
PBMC 
isolation 
2.0 / 3.8 6.4 5.7 6.6 1.2 n/a 8.9 6.4 n/a n/a 
Days in 
hospital / on 
ICU 





N / 0 N / 0 N / 0 Y / 0 N / 0 Y / 0 Y / 0 Y / 0 Y / 3 N / 0 






AB, HCQ N 
Follow Up Outcome discharged discharged discharged discharged discharged discharged discharged discharged discharged discharged 
PBMCs from ten COVID-19 patients were included in immunoglobulin repertoire studies. General information, patients’ history, symptoms of 
SARS-CoV-2 infection, disease course and outcome are listed for each donor. SARS-CoV-2 IgG is given as a ratio of optical density from 
time point of PBMC isolation (± one day).  
Abbreviations: m = male, f = female, Y = yes, N = no, n/a = not available, CVD = cardiovascular disease, PY = pack years, AB = antibiotics, 
ACT = anticoagulation therapy, APT = antiplatelet therapy, HCQ = hydroxychloroquine. 
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HL CV01-101  ASC IgM 3-74 3 ARGSSNLFDI 7 1-44 3 AAWDDSLNGWV 4 0.1      
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
     
    
 
HL CV01-102  ASC IgG1 3-21 4 ARSGGYSGYDYSHRIDY 25  2-14 3 SSYTLDSTVV 12  n.exp.   
HK CV01-103  ASC IgA1 1-69 4 ASGWGMEYSSSSADY 0 3-11 2 QQRSNWPPYT 1 0.09   
HL CV01-104 1-2 ASC IgM 1-18 4 ARADETMVQGVIPNFDY 4 2-8 2 SSYAGSNNVV 3 0.1   
HK CV01-107  ASC IgA2 3-74 6 ARGRDCGGSSCYGYPYYGMDV 7 2-28 2 MQALHTPYT 4 n.exp.   
HK CV01-109 1-3 ASC IgG2 3-7 4 ARAGSVGVVDY 12  2-30 1 MQGTHWPWT 8 0.1   
HK CV01-110  ASC IgA1 3-7 4 VRDRGYCVGDVCYTVLDY 27  1-6 4 LHDYNYPPT 13  0.09   
HK CV01-111  ASC IgM 3-15 1 TTWFYYDIRDH 24  3-11 2 QQRSNWPPFT 11  0.09   
HL CV01-112 1-2 ASC IgM 1-18 4 ARADDTMVQGVIPNFDY 14  2-8 3 SSYAGSNNVV 2 0.03   
HK CV01-113  ASC IgM 3-15 4 ASIYYDF 13  1-17 2 LHYNSVPYT 18  n.exp.   
HL CV01-114  ASC IgM 1-2 4 ARGDAVARTLNLDY 8 1-44 2 AAWDDSLNGV 3 0.09   
HK CV01-116 1-3 ASC IgM 3-7 4 ARAGNIGAVDY 14  2-30 1 MQGTHWPWT 1 0.02   
HL CV01-117  ASC IgA1 3-49 4 GLSYYYDNGGYYSVPPIDV 20  2-8 3 SSYADSNNLV 9 n.exp.   
HK CV01-118 1-1 ASC IgM 3-9 3 AKNSPSCADAVCYFDV 10  4-1 1 QQYYSAPRT 8 n.exp.   
HK CV01-120  ASC IgA1 4-30-4 3 AREGVLITIFGVARDAFDI 1 3-20 2 QQYGSSPRT 1 0.09   
HK CV01-121  ASC IgA1 4-38-2 4 SIWGGVQGVLQDY 22  3-15 2 QQYNDWPRT 7 0.09   
HK CV01-122 1-3 ASC IgG2 3-7 4 ARAGSIASVDY 11  2-30 1 MQGTHWPWT 8 n.exp.   
HK CV01-123  ASC IgM 3-7 4 AKGGWRYFDY 16  3-11 4 QQRSSWPLT 9 0.08   
HK CV01-124  ASC IgM 3-23 4 AKYGSITIFGVVIIGYFYFDY 1 3-20 2 QQYGSSPAT 0 0.08   
HL CV01-125 1-2 ASC IgA1 1-18 4 ARADYTMVQGVIPNFDY 7 2-8 2 SSYAGSNNVL 10  0.1   
HL CV01-126  ASC IgA2 5-51 6 AGHVRYCISTNCYHYGMDV 5 5-45 3 MIWHTSAWV 6 0.10   
HK CV01-128 1-3 ASC IgG2 3-7 4 ARAGDRGAVDY 13  2-30 1 MQGTHWPWT 8 0.11   
HL CV01-129 1-2 ASC IgA1 1-18 4 ARADYTMVQGVIPNFDY 0 2-8 2 SSYAGSNNVV 4 n.exp.   
HK CV01-130  ASC IgM 3-7 3 ARPGYSGNNWGEAFDI 0 4-1 1 QQYYDTLWT 13  0.09   
HK CV01-132  ASC IgG1 4-59 6 ARDRGYNWNYYYYYGMDV 0 3-20 1 QQYGSSPST 2 0.1   
HK CV01-133 1-3 ASC IgG2 3-7 4 ARAGSRGSVDY 21  2-30 1 MQGTHWPWT 13  0.1   
HK CV01-134  ASC IgM 3-30 6 AKEKLDCSSTSCYFGFIYYYYYMDV 0 1-12 2 QQANSFPLT 1 0.09   
HL CV01-135  ASC IgG1 3-11 4 ARESYEGSSFDY 10  6-57 3 QSYDSSNRRV 3 0.1   
HK CV01-137  ASC IgG2 3-7 4 ARDYGRCGDY 18  3-11 2 QQGGNWPRT 9 0.11   
HK CV01-138  ASC IgA1 4-39 5 ARHGYITIFGVVIIPGWFDP 0 3-15 1 QQYNNWPPWT 2 0.07   
HL CV01-139  ASC IgM 4-39 4 ARHPDNELLPFDY 0 3-21 1 QVWDSSSDSYV 2 0.11   
HK CV01-140  ASC IgM 3-30-3 2 ARDPRNYCHSNTCPVWYFDL 17  3-20 2 QQYGSSPRT 6 0.08   
HL CV01-141  ASC IgG1 3-33 4 AREGNYGDYGGSFDY 0 3-10 3 YSTDSSGNHRV 0 n.exp.   
HL CV01-142  ASC IgM 4-30-4 2 ARGPRITIFGVVIYWYFDL 0 1-40 2 QSYDSSLSGSGV 1 0.09   
HL CV01-144  ASC IgG1 3-30 4 ARRDRIFEFGATREALDF 22  1-40 1 QSYDSSLSGYV 15  0.08   
HK CV01-145  ASC IgM 3-23 5 AKVTWTTTGDS 19  1-5 1 QQYNSYPWT 7 0.10   
HK CV01-146 1-3 ASC IgG1 3-7 4 ARAGDRGAVDY 17  2-30 1 MQGTQWPWT 10  0.09   
HK CV01-147  ASC IgG1 3-30-3 5 ARERVNGRWLQLLTP 20  1-5 4 QQYDAYLS 16  0.09   
HK CV01-148 1-3 ASC IgM 3-7 4 ARAGDRGAVDY 10  2-30 1 MQGTHWPWT 2 0.08   
HK CV01-149  ASC IgM 1-18 4 AGYPRYNWNYDNRYYFDF 7 1-39 5 QQSYSAPIT 9 n.exp.   
HL CV01-151 1-2 ASC IgM 1-18 4 ARADDTMVQGVIPNFDY 2 2-8 2 SSYAGSNNVV 4 0.07   
HK CV01-152  ASC IgA1 1-3 6 ARGVGATIPYYYYYYMDV 2 1-5 1 QQYNSYSWT 1 0.1   
HK CV01-153  ASC IgG1 4-4 6 AKVGGGNADHGPGYYYYYMDV 37  1-9 2 QELNRYPRT 17  0.07   
HK CV01-154 1-1 ASC IgM 3-9 3 AKNSASCADDLCYFDI 15  4-1 1 QQYYSGPRT 7 0.08   
HK CV01-155  ASC IgM 3-11 4 ARALPGGITIFGVVITEYYFDY 0 3-20 2 QQYGSSSYT 2 0.08   
HL CV01-158  ASC IgG2 3-21 3 ARGDDYGEYTGAFDA 2 3-1 2 QAWDSSTVV 3 0.09   
HK CV01-159  ASC IgA1 1-46 4 ARGGETQQRLVWDQKTDD 23  1-17 4 LQYNSYPLT 12  0.11   
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HK CV01-163 1-3 ASC IgA1 3-7 4 ARAGSVGTVDY 22  2-30 1 MQGTHWPWT 16  0.08   
HK CV01-166  ASC IgA1 3-15 4 TTEKGRYHLGGVFAN 11  4-1 4 QQYYSTPLT 8 n.exp.   
HL CV01-168  ASC IgA1 5-51 4 VWTSRGYFDH 6 7-43 3 LFYYGGAWV 9 n.exp.   
HL CV01-169  ASC IgM 3-30 4 ARDLSSGWSLDS 3 2-14 3 SSYTSSNTWV 4 0.07   
HL CV01-170  ASC IgM 4-4 6 ARYCSSTSCYGYYYYGMDV 0 2-8 1 SSYAGSISYV 2 0.08   
HK CV01-171  ASC IgG1 4-4 3 AKGGGSGWYYDAFDI 17  3-15 1 QQYNNWLRT 12  0.11   
HL CV01-174  ASC IgM 1-18 4 ARDDWNYARGNFDY 3 2-14 2 SSYTSSSSVV 1 0.14   
HK CV01-175 1-3 ASC IgM 3-7 4 ARAGGVGTVDY 11  2-30 1 MQGTLWPWT 2 0.1   
HL CV01-176 1-2 ASC IgA1 1-18 4 ARADHTMVQGVIPNFDY 3 2-8 2 SSYTGRKNVV 6 0.1   
HK CV01-180 1-3 ASC IgM 3-7 4 ARCDMAGTTDY 5 2-30 1 MQGTLWPWT 2 0.1   
HK CV01-181  ASC IgG1 3-21 2 ARDLEGVETIFGVVIIPAYWYFDL 0 2-28 4 MQALQTRLT 3 0.08   
HL CV01-182  ASC IgG1 3-23 4 AKDLKIGTLGWYYDFWSGYLPDPSNKIFDY 0 1-40 3 QSYDSSLSGWV 0 0.1   
HL CV01-183  ASC IgM 3-73 3 TRVNPIQGAFYDALDI 6 1-51 2 GTWDSSLSVVV 7 0.11   
HK CV01-184  ASC IgG2 4-59 4 ARFSSAAGVWALDH 11  4-1 2 QQYYTTPFT 7 n.exp.   
HL CV01-185  ASC IgA1 1-69 6 ACDMVQGVAVLDV 13  2-14 2 SSYTSSSTVV 9 0.13   
HK CV01-186  ASC IgG2 4-59 5 ARHGKSIPYSNYDWFDP 0 1-39 3 QQSYSTLPFT 0 0.09   
HK CV01-188  ASC IgM 3-72 4 ARDLGANGDRFGN 4 4-1 1 QQYYSTPLT 2 0.08   
HK CV01-193  ASC IgA1 3-15 4 ATDLGDYGDYMRS 13  1-12 2 QQANSFPYT 7 0.11   
HL CV01-194  ASC IgM 4-59 4 AKKADPHSAFDY 6 2-11 1 CSYAGSYTYV 6 0.09   
HL CV01-195  ASC IgM 3-7 1 VRELVVGRAEYFQD 0 1-44 2 AAWDDSLNGRV 1 3.37 ++ >250 
HK CV01-196  ASC IgG1 3-30 3 AKDPGMLYPSAFDM 14  3-15 4 QQYNNWPPLT 13  n.exp.   
HL CV01-197  ASC IgM 3-23 4 AKDQDGHYGGNPDMDH 10  2-8 3 SSYAGSNKMV 11  n.exp.   
HL CV01-198  ASC IgG2 3-15 4 ATLTYGYSPY 11  2-14 1 SSYTSSTTYV 63  n.exp.   
HK CV01-199  ASC IgA1 3-74 4 ASNFNRNDGY 14  2-30 4 IQSTHWPPN 13  n.exp.   
HK CV01-202  ASC IgG1 4-30-4 4 ARMGNMFGYSVVDF 22  1-39 2 LQTYSAPYT 20  n.exp.   
HL CV01-203  ASC IgA2 3-30 6 AKSEGKFYFYGVDV 9 1-47 1 AACDDSLSGHV 3 n.exp.   
HK CV01-205  ASC IgG1 5-51 5 AREARWSFPSWFDP 6 3-15 2 QQYNNWPRF 7 n.exp.   
HK CV01-211  ASC IgA1 5-51 4 ARLSSGWYGGFNFDY 0 3-20 2 QQYGSSPVYT 0 n.exp.   
HL CV01-212  ASC IgM 3-30 4 AKCSYTSICKGWDGAH 14  2-14 2 SSFTTSYTLV 11  n.exp.   
HK CV01-213  ASC IgG1 3-64 4 ARLQGTGYLDY 12  3-20 2 HQYGSSPRT 9 n.exp.   
HL CV01-215  ASC IgM 3-48 5 ARQWAVNWFVP 7  2-14 2 SSHTSSSTVV 8 n.exp.   
HK CV01-220  ASC IgA1 3-48 6 ARDVGTYESTSTGMDV 7 3-11 5 QQRGNWPPAT 11  n.exp.   
HL CV01-221  ASC IgA1 3-30-3 4 ARGAPVDY 6 2-8 7 N/A 9 n.exp.   
HL CV01-222  ASC IgA1 3-23 4 AKPGGEWYSSGWRFDY 2 1-47 2 AAWDDSLSGPV 0 n.exp.   
HL CV01-223  ASC IgM 3-23 3 AKCGRTSCRVDAFDI 27  8-61 3 VLSMGGGVWV 13  n.exp.   
HL CV01-225  ASC IgA1 3-53 3 ARDGGGSYPHRAFDI 1 2-14 2 SSYTSSSTSDVV 2 n.exp.   
HL CV01-226  ASC IgG1 4-39 6 ARHATGTPPYYYYYMDV 2 3-1 1 QAWDSSTACV 3 n.exp.   
HL CV01-227  ASC IgA1 3-30 4 AKGSPLLGFGGVDY 0 5-39 3 AIWYSSSLV 1 n.exp.   
HK CV01-228  ASC IgA1 3-7 4 ARVGASDYDYVWGTRTLDS 11  4-1 1 QQCLTTPPWT 12  n.exp.   
HK CV01-229  ASC IgG2 5-51 4 ARPYGAGTAHYFDY 9 4-1 4 QQYYGTPHT 8 n.exp.   
HL CV01-231 1-4 ASC IgA1 4-39 6 ARHFHPGNYYYYYMDV 6 3-1 2 QAWDSSTYVV 3 n.exp.   
HL CV01-232  ASC IgM 4-39 4 ARKYGDLHFDY 1 8-61 3 VLYMGSGISV 3 n.exp.   
HL CV01-233  ASC IgM 4-39 3 ARSDARFLEWLFPDAFDI 3 2-23 2 CSYAGSTTFVV 3 n.exp.   
HL CV01-234  ASC IgM 3-30 5 ARGSPFGGIRSGLGP 20  1-27 1 QKYNSAPWT 11  n.exp.   
HL CV01-238 1-4 ASC IgG1 4-39 6 ARHPTGSGSYQYYYYYIDV 3 3-1 2 QAWDSSTVV 2 n.exp.   
HL CV01-241  ASC IgA1 3-66 3 ARDRGYDSSGYTAADAFDI 2 1-5 1 QQYNSYST 6 n.exp.   
HL CV01-242  ASC IgG1 4-31 5 ARGGYRNWFDP 3 2-11 3 CSYAGSYTWV 2 n.exp.   
HK CV01-244  S1-MBC IgG1 5-10-1 6 ARLKGSVPPYYYNYMDV 18  2-28 4 MQGLQTPFI 7 n.exp.   
HK CV01-249  S1-MBC IgA1 3-30-3 3 ARHNRAQGPSFDV 21  1-39 5 QQTYSVPTT 32  0.08   
HK CV01-254  S1-MBC IgM 3-7 4 ASLLGGTVVNDY 4 4-1 2 QQYYSTQYT 2 0.09   
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HK CV01-257  S1-MBC IgM 3-48 6 ARHPWDDYGDYYYYYMDV 5 3-20 2 QQYGSSLNT 2 10.92 ++ >250 
HL CV01-258  S1-MBC IgG1 4-59 6 ARAVHGVDTGMVTYYYHYYMDV 7 3-21 2 QVWDNSIDHVV 5 0.08   
HL CV01-260  S1-MBC IgA2 1-8 4 ARGREYYDFWSGYYN 3 2-14 3 SSYTRSNTVV 6 0.14   
HK CV01-266  S1-MBC IgA1 3-15 3 TSERWLDAFDI 28  1-39 5 QQSYRSPPIT 24  n.exp.   
HL CV01-273  S1-MBC IgA1 4-4 4 ARGWGKGPPLGY 2 2-23 3 YSYAGSSTWV 4 7.10 - >250 
HK CV01-274  S1-MBC IgM 3-30 4 AKDNGDYACFDY 0 4-1 4 QQYYSTPLT 0 0.07   
HL CV01-276  S1-MBC IgA1 1-2 6 ARDPFEYYDFWSGYYRGGMDV 2 2-14 3 SSYTSSSTRV 1 n.exp.   
HK CV03-101  ASC IgG1 1-2 4 ARGLITWYYYYDSSAVDY 0 3-20 1 QQYGSSPWT 0 0.1   
HK CV03-103  ASC IgM 3-21 5 ARDPDGHRSGWFDWFDP 3 1D-12 5 QQANSFPIT 4 n.exp.   
HL CV03-104  ASC IgG1 1-18 6 ARDSHYYDSSGYYYLYYYYGTDV 1 3-25 1 QSADSSGTYV 0 0.09   
HK CV03-106 3-2 ASC IgG1 4-31 3 ARGRTIFGVVSGAFDI 0 3-20 4 QQYGSSPLT 1 0.02   
HK CV03-107 3-2 ASC IgG1 4-31 3 ARGRTIFGVVSGAFDI 0 3-20 4 QQYGSSPLT 2 0.10   
HL CV03-108  ASC IgG1 3-15 6 TKTKNPPAYDFWSGYYRGRPPYYKYGMDV 20  1-40 1 QSYDNSLSEYDDV 10  0.1   
HL CV03-109  ASC IgG1 5-10-1 4 ARHVGVGATHSPPFDY 0 1-40 2 QSYDSSLSGPTV 0 0.12   
HK CV03-110  ASC IgG1 3-48 4 ARDLGSWYYLLDFDY 1 1-5 1 QQYNSYPRT 0 0.08   
HK CV03-112  ASC IgG1 3-48 5 GRSSSWRYNWFDP 20  3-15 1 QQYNNWPPWT 13  0.03   
HL CV03-113  ASC IgG1 3-15 4 TTDPYYEISSGYSPDY 44  2-11 2 N/A 34  0.09   
HL CV03-116  ASC IgA1 4-59 6 ARVQGRGSGSYYSAYYYGMDV 0 1-40 1 QSYDSSLSGV 1 0.1   
HL CV03-117 3-3 ASC IgG1 1-46 6 LRDGISTFGVVNHYYAMDV 16  2-14 1 SSYTSSSTVV 11  n.exp.   
HL CV03-118 3-3 ASC IgG1 1-46 6 ARDGISTFGVVKHYYAMDV 26  2-14 1 SSYTTTTTLV 26  n.exp.   
HL CV03-120  ASC IgG1 3-21 6 ARDSLITIFGVVIEAPDDYGMDV 0 2-14 2 SSYTSSSTVV 2 n.exp.   
HL CV03-121 3-1 ASC IgG1 3-23 4 AKDYFVIPPAALYDY 0 1-51 2 GTWDSSLSAGV 3 n.exp.   
HL CV03-123  ASC IgG1 3-23 5 VKELDDQLTLGGWFDP 36  2-23 3 CSYVGTATVV 26  0.11   
HL CV03-124  ASC IgG1 5-51 4 ASSVRYFDWFDFDY 0 1-44 1 AAWDDSLNGYV 0 n.exp.   
HK CV03-129  ASC IgG1 1-69 4 ARARRPTYSSSWGTFDY 0 1-39 1 QQSYSTPWT 0 0.09   
HK CV03-130  ASC IgG1 4-59 4 ASGTYGGPYLFDY 19  1-5 1 QKYNTYPGT 12  n.exp.   
HK CV03-131  ASC IgM 3-11 4 ARAGDMIVVAAFDY 0 3-20 4 QQYGSSPLT 0 0.08   
HK CV03-132  ASC IgG1 3-7 6 ARGPQMVYALFPYYYYYGMDV 0 1-27 1 QKYNSAPWT 0 0.1   
HK CV03-135  ASC IgG1 3-64 3 VMELYGSDVFDL 22  1-39 1 QQSYSTSWT 18  0.1   
HL CV03-138  ASC IgM 3-74 4 ASYTWGRI 1 2-14 2 SSYTRSSTLVV 2 0.08   
HK CV03-139  ASC IgM 4-39 6 ASQGPLPPILYDILTGYYLGDYYYGMDV 2 2-28 4 MQALQTPLT 1 0.09   
HK CV03-140  ASC IgG1 3-49 4 TRDAYYYGSGSYSEGGH 0 3-11 3 QQRSNWPPLFT 0 0.09   
HK CV03-141  ASC IgG1 4-38-2 6 ARDVTGYDNEDYYYYYGLDV 24  4-1 1 QQYYSSPRT 9 0.08   
HL CV03-142  ASC IgM 3-53 4 AREGPDSGYLDY 7 4-69 3 QTWGTGIRV 6 0.11   
HK CV03-143  ASC IgG1 3-48 4 ARDSGFWSGYYPGNFNY 0 1-33 4 QQYDNLPPLT 1 6.43 ++ >250 
HK CV03-144  ASC IgG1 1-18 6 ARDPWIELRPPRNYYYNGMDV 11  2-28 1 MQALQTPRT 4 0.08   
HL CV03-145  ASC IgG1 1-46 4 ARDSSDCSGGSCYRFDY 0 1-44 1 AAWDDSLNGYV 0 n.exp.   
HK CV03-146  ASC IgM 3-23 4 AKDRTVTKTGLFYLDDC 10  1-39 5 QQSYSTPIT 6 0.08   
HL CV03-147 3-4 ASC IgA1 3-23 4 ASQTGTGEVDY 0 3-1 1 QAWDSSTGV 0 4.2 - n.t. 
HL CV03-148 3-1 ASC IgG1 3-23 4 AKGPRLLWFGELSPFDY 1 1-51 2 GTWDSSLSALV 1 4.58 - n.t. 
HL CV03-150 3-5 ASC IgA1 3-23 6 VKGSGDIERMVSTLRYYFYGLEV 22  1-47 3 AVWDDSLSAWV 12  n.exp.   
HL CV03-151 3-5 ASC IgA1 3-23 6 VKGSGDIERMVSTLRYYFYGLDV 17  1-47 3 AVWDDSLSAWV 10  n.exp.   
HL CV03-152  ASC IgG1 3-30 4 AKSGEVFWFGRFRRDYLDY 11  1-44 2 AAWDDRLNGVV 12  0.1   
HK CV03-153  ASC IgM 3-74 4 ARDSCTSTSCYESMK 7 1-5 1 QHYNSYPWM 5 0.12   
HK CV03-154  ASC IgG1 1-24 6 ATSTVIAAAGTVHYYYYYGMDV 0 2-24 2 MQATQFPYT 0 0.11   
HK CV03-155  ASC IgG1 3-33 6 ARDEKAYDFWSGYLSYYYYGMDV 1 2-30 2 MQGTHWPPYT 0 0.09   
HK CV03-156  ASC IgG1 5-10-1 4 ARLLYYYDSSGYYLPSPIDY 0 1-33 4 QQYDNLLLT 0 0.54 ++ >250 
HL CV03-158 3-5 ASC IgA1 3-23 6 VKGSGDIERMVSTLRYYFYGLDV 16  1-47 3 AVWDDSLSAWV 10  0.1   
HL CV03-160  ASC IgM 5-10-1 4 ARLGADSSGYYLPSGGIGY 1 1-40 3 QSYDSSLSGSKV 0 0.09   
HL CV03-161  ASC IgG1 4-39 2 ARQRKGWLQLRGNWYFDL 2 3-10 2 YSTDSSGNQVV 0 0.09   
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HL CV03-162  ASC IgM 3-74 4 ARGGGTVVTPGPDY 11  4-69 2 QTWGIGTHDVI 6 0.07   
HL CV03-163 3-5 ASC IgG1 3-23 6 VKGSGDIERMVDALRYYFYGMDV 27  1-47 3 AAWDDSLSAWV 15  1.17 - n.t. 
HK CV03-166  ASC IgA1 4-4 5 TRLYCSSGACYLGP 26  3-20 1 QQYGRSPT 12  0.08   
HL CV03-167  ASC IgG1 1-46 5 ARGRDWFDP 1 2-23 3 CSYAGSSTWV 5 0.11   
HK CV03-168  ASC IgG1 1-69 6 AREAFYDILTGYSSTPNHYYYGMDV 0 2-28 1 MQALQTPWT 0 0.1   
HK CV03-169  ASC IgG1 3-74 4 ARDFYYDSSGFDY 0 1-39 1 QQSYSTPPWT 0 7.53 - n.t. 
HL CV03-170  ASC IgG3 4-4 3 ARDTIGGHAFDI 0 3-21 3 QVWDSSSDHRV 2 0.09   
HL CV03-172  ASC IgG1 1-24 5 ATSTLFSSVVPASWFDP 0 2-14 2 SSYTSSSTPVV 0 0.09   
HK CV03-173  ASC IgM 1-2 3 ARILPSDYFWSGYYSIQETDAFDI 0 1-5 2 QQYNSYSSS 0 0.08   
HK CV03-174  ASC IgG1 5-51 4 ARQVFIAVAGTGFDY 1 2-28 1 MQALQTPWT 0 2.68 - > 250 
HL CV03-175  ASC IgG1 4-31 5 ARDFVSGPLMTENVPIYDSSGYYLTRYNWFD
P 
0 1-51 2 GTWDSSLSAVV 3 0.1   
HL CV03-177 3-4 ASC IgG1 3-23 4 AKDSGSYLLN 0 3-1 1 QAWDSSTYV 1 3.3 - n.t. 
HL CV03-179  ASC IgG1 1-2 6 AREDGSSPLGGGMDV 0 3-1 1 QAWDSSTYV 1 0.09   
HL CV03-180 3-5 ASC IgA1 3-23 6 VKGSGDIERMVSSLRYYFYGLDV 15  1-47 3 AVWDDSLSAWV 12  0.09   
HK CV03-181  ASC IgG1 1-69 4 ASTGHHQDASDY 0 3-11 3 QQRSNWPPRVT 0 0.07   
HL CV03-182  ASC IgG1 1-2 4 ARERLAAAGTDFDY 1 1-40 1 QSYDSSLSDYV 2 0.09   
HL CV03-183 3-5 ASC IgA1 3-23 6 VKGSGDIERMVSSLRYYFYGLDV 15  1-47 3 AVWDDSLSAWV 10  0.13   
HL CV03-185  ASC IgG1 4-4 6 ARRGHTLLWYYYYGMDV 0 1-51 7 GTWDSSLSAGAV 2 1.82 - > 250 
HL CV03-186  ASC IgG1 3-48 6 ARGQRGLPFYYYYGMDV 0 1-40 1 QSYDSSLSGSV 0 0.12   
HL CV03-188 3-5 ASC IgA1 3-23 6 VKGSGDIERMVSTLRYYFYGLDV 16  1-47 3 AVWDDSLSAWV 14  0.08   
HK CV03-190  ASC IgG1 4-4 6 ARGMGYDFWSGYSSYYGMDV 0 1-16 4 QQYNSYPLT 0 0.35 - > 250 
HK CV03-191  ASC IgM 3-11 4 ARDLGYNRRFDY 0 1-33 4 QQYDNLPLT 1 6.16 ++ > 250 
HK CV03-192  ASC IgG1 3-15 6 TTDPLRYYDSSGYLYYGMDV 1 2-28 4 MQALLTPST 1 0.12   
HL CV03-193  ASC IgM 3-53 3 ARGGSWPNVFDI 11  8-61 3 VLYMGSGIWV 8 0.1   
HL CV03-195  ASC IgG1 1-18 6 ARDRLRVRGVIKYYYYGMDV 0 3-25 3 QSADSSGTHWV 2 0.17   
HK CV05-101  ASC IgA1 3-30 4 AKDRGYSSSWFSYLDS 13  3-20 4 QQYGSLRLT 9 n.exp.   
HK CV05-102 5-1 ASC IgM 1-3 3 AREDTFSVFGVVTRGNAYDV 26  3-20 1 QQYGVSPRT 18  n.exp.   
HK CV05-104  ASC IgA1 5-51 4 ARLGRSLQPNLGFDL 28  2-30 4 MQGSHWPLT 23  0.14   
HK CV05-107  ASC IgG1 3-21 4 ARDSESAWNRIGNFYFDL 34  3-15 5 QQYNDWLIT 19  0.07   
HK CV05-108  ASC IgG1 5-10-1 6 ARHHLKRGYATRYGMDV 0 1-39 1 QQSYSTPWT 0 0.12   
HK CV05-109  ASC IgA1 4-31 4 ASLEGPYCSDTTCYEGGQGLDY 11  3-11 1 HQRGNWWT 6 0.09   
HK CV05-110 5-1 ASC IgG1 1-3 3 AREDTFSVFGVVTRGNAYDV 26  3-20 1 QQYGVSPRT 18  0.08   
HL CV05-111  ASC IgA1 3-33 6 ARDLDGDYVTYYYGMDV 1 2-14 2 SSYTSSSTPVV 1 8.39 ++ > 250 
HK CV05-113  ASC IgG1 3-30 2 ASGDGYRNFWYFDI 31  2-28 4 MQALQTPT 13  0.09   
HL CV05-114  ASC IgG1 3-30-3 4 ARTVGDYGDY 0 3-1 2 QAWDSSTVV 0 0.27   
HK CV05-115  ASC IgG1 3-48 6 ARDRGGYSGYGPYYYGMDV 0 1-39 1 QQSYSTPWT 0 5.17 - n.t. 
HL CV05-116  ASC IgA1 4-38-2 1 N/A 58  2-23 3 CSYAGAGSSNVV 18  n.exp.   
HK CV05-117  ASC IgM 3-23 6 AKEKTSWLVAYYYGLDV 31  1-9 2 QQVNSHPHT 13  0.11   
HK CV05-118 5-2 ASC IgA1 4-31 3 ARDYPFCGADCPWVDVFDI 23  3-15 1 QQYSNWPRT 30  0.09   
HK CV05-119  ASC IgG1 3-30 4 AKPVGSSGYYEGGKPIDY 0 1-5 1 QQYNSYWT 3 0.12   
HL CV05-119  ASC IgG1 3-30 4 AKPVGSSGYYEGGKPIDY 0 3-21 3 QVWDSSSDHWV 2 0.1   
HL CV05-120  ASC IgG1 5-51 4 ARNRAGVIDY 0 6-57 3 QSYDSSNLWV 1 0.09   
HL CV05-121  ASC IgA1 1-8 3 VRERIDYDHSGVSTSAFEF 27  1-44 1 GGWDDSLNGYV 17  0.09   
HL CV05-122  ASC IgG1 3-23 6 AKGGYCSGGNCKMAHSYYGLDV 21  1-47 3 AAWDDSLSGHWV 7 0.07   
HK CV05-125  ASC IgM 4-39 5 ASSNTASTMIVVVVQRNWFDP 0 3-15 5 QQYNNWPPIT 1 0.1   
HK CV05-126  ASC IgG1 3-48 4 ARDRARAKWLAYSNYFDY 0 3-15 5 QQYNNWPL 0 0.11   
HL CV05-127  ASC IgG1 3-33 4 ARDRVSSWEYYFDY 0 3-10 2 YSTDSSGNHRGV 1 0.12   
HL CV05-129 5-3 ASC IgG1 4-59 6 ARDRVSGGMDV 0 3-21 2 QVWDSSSDHVV 2 n.exp.   
HL CV05-131  ASC IgA2 3-23 4 ARGYIGYCSGSTCTTNGGGDY 23  1-51 2 VTWDSSLSAGV 8 n.exp.   
HL CV05-134  ASC IgA1 3-23 3 AKAGIRGGISMVRAHFDI 6 2-8 1 SSYAGSNNFV 1 0.08   
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HK CV05-135  ASC IgG1 3-33 4 AREDTAMVQRFDY 0 1-39 2 QQSYSTHT 0 0.11   
HL CV05-135  ASC IgG1 3-33 4 AREDTAMVQRFDY 0 3-1 2 QAWDSSNVV 2 0.1   
HK CV05-136  ASC IgG1 1-69 6 ARGRDIVVESTDQDPMDV 14  4-1 5 QQYYSTSSIT 6 0.07   
HK CV05-138 5-2 ASC IgA1 4-31 3 ARDYPFCGADCPWVDVFDI 15  3-15 1 QQYNNWPRT 12  0.06   
HL CV05-139  ASC IgG3 3-23 6 AKDFSGANGDYYYYGMDV 0 3-25 3 QSADSSGTWV 2 0.09   
HK CV05-140  ASC IgG1 4-59 4 AAGGGSGFYYF 30  1-5 2 QQYKSSSST 19  0.09   
HL CV05-143  ASC IgG1 4-59 4 ARDRVAAGVDY 1 3-21 2 QVWDSSSDHVV 2 0.09   
HL CV05-144  ASC IgG1 3-30-3 6 ARTPGDGMDV 0 3-10 2 N/A 1 0.1   
HL CV05-145  ASC IgG1 5-10-1 4 ARHAIYCSGGSCYAYFDY 1 1-41 2 N/A 3 n.exp.   
HK CV05-146 5-2 ASC IgA1 4-31 3 ARDYPFCGADCPWVDVFDI 22  3-15 1 QQYNNWPRT 24  0.09   
HK CV05-148  ASC IgG1 4-39 4 ARQRTHTIFGVVVHFDY 1 4-1 1 QQYYSTPWT 1 0.1   
HK CV05-149  ASC IgA1 4-59 6 ARGWGFPGSTNVHFYFYGLDV 29  1-9 1 QQLNSYRT 16  0.1   
HL CV05-151  ASC IgM 4-59 6 AAGEVVTAISYYYYGMDV 0 3-1 2 QAWDSSSVV 2 0.4 - >250 
HK CV05-152  ASC IgM 3-15 4 TTERIYDYVWGSYRYSDY 1 3-20 3 QQYGSSPVT 1 0.09   
HK CV05-153  ASC IgA1 4-4 4 ARDLNV 28  3-15 3 QQYVNWPFT 26  0.07   
HK CV05-155  ASC IgM 1-2 6 ARALRITMIVVVTHYGMDV 0 3-20 2 QQYGSSPYT 0 0.1   
HK CV05-157  ASC IgG1 3-48 4 ARDKSDFWSGNFDY 15  1-33 2 QQYDNLLVT 7 0.1   
HL CV05-159  ASC IgG1 4-38-2 4 ARDKVDYYPYYFDY 1 3-21 2 QVWDSSSDHRV 2 0.08   
HK CV05-162  ASC IgG2 3-21 4 ARDQWSGTTVTSMGH 15  1-5 2 QQYDSNWYT 15  0.09   
HK CV05-163  ASC IgG1 1-2 6 AREVMVRGALPPYGMDV 0 3-11 4 QQRSNWPPVT 0 10.44 ++ 25-250 
HK CV05-164 5-2 ASC IgA1 4-31 3 ARDYPFCGADCSWVDVFDI 21  3-15 1 QQYNNWPRT 13  0.1   
HK CV05-165  ASC IgA1 3-74 4 AREGGDGFDY 13  1-5 4 QQYQSYPLA 14  0.1   
HK CV05-167  ASC IgG1 1-69 3 ARGVEMATILPDDAFDI 0 3-15 4 QQYNNWPPVT 0 0.09   
HL CV05-169  ASC IgA1 1-69 4 ARGSTHNNLFVMDY 22  7-46 2 FLSYSGVRGLFVV 17  0.06   
HL CV05-170  ASC IgG1 1-2 6 ARVDTTGTTFWLYYYYGMDV 0 3-1 2 QAWDSSTALVV 1 0.11   
HK CV05-171  ASC IgG1 4-30-4 4 ARLHGDYYYFDY 0 1-39 2 QQSYSTHT 5 n.exp.   
HL CV05-171  ASC IgG1 4-30-4 4 ARLHGDYYYFDY 0 3-1 2 QAWDSSVV 0 0.09   
HK CV05-172  ASC IgM 4-30-4 5 ARLSMTTVTRGNWFDP 0 1-39 2 QQSYSTHT 0 0.08   
HL CV05-174  ASC IgG1 1-2 4 ARDLSNSGSSFDY 0 3-1 2 QAWDSSTADVV 0 0.11   
HK CV05-175  ASC IgG1 1-46 3 VQDLGVRGGRRALDV 22 2-28 2 FQALQTPYT 7 0.11   
HK CV05-176  ASC IgG1 3-53 5 ARGYPGGP 0 1-33 4 QQYDNLLT 0 0.18   
HK CV05-178  ASC IgA2 3-23 3 AKDALGFCSGTSCYGEGAFDI 19  1-5 2 QQYNSYPYT 10  0.07   
HL CV05-178  ASC IgA2 3-23 3 AKDALGFCSGTSCYGEGAFDI 19  2-23 3 CSYAGSSTWV 2 n.exp.   
HK CV05-181  ASC IgG1 3-30-3 6 ARDLQYYDFWSGYLGTPGRYYYYGMDV 0 3-20 1 QQYGSSPPWT 0 0.07   
HL CV05-182 5-3 ASC IgG1 4-59 6 ARDRVSGGMDV 0 3-21 2 QVWDSSSDHVV 1 n.exp.   
HK CV05-183  ASC IgG1 3-30-3 6 ARDLRFLEWLFNVPYYYYYGMDV 0 1-9 2 QQLNSYPYT 0 0.11   
HL CV05-183  ASC IgG1 3-30-3 6 ARDLRFLEWLFNVPYYYYYGMDV 0 2-23 3 CSFAGGITLV 14  n.exp.   
HK CV05-185  ASC IgM 3-15 4 TTDRTYDYVWGSYRYRDY 0 1-39 4 QQSYSTLPRT 1 0.06   
HK CV05-187  ASC IgG2 3-73 4 TTIGSGYGFGH 10  1-39 2 QQSYSTHT 1 n.exp.   
HL CV05-187  ASC IgG2 3-73 4 TTIGSGYGFGH 10  2-11 2 CSYGGTYVL 11  0.1   
HL CV05-189  ASC IgG1 3-9 6 AKAHSDPNYDFWSPDYYGMDV 1 2-14 2 SSYSTSSTKEV 5 0.10   
HL CV05-190  ASC IgG1 3-30-3 4 ARGVYGDSGVDY 1 3-21 1 QVWDSSSDHLYV 1 0.08   
HK CV05-191  ASC IgG2 3-11 6 ARDTSQSHMDV 15  2-30 2 MQGTHWPPYT 6 0.08   
HK CV05-192 5-1 ASC IgG1 1-3 3 AREDTFSVFGVVTRGNAYDV 26  3-20 1 QQYGVSPRT 20  0.11   
HL CV05-194  ASC IgG1 3-74 1 ARDRHTYSLEYFQH 0 6-57 3 QSYDSSNQV 1 0.08   
HL CV05-195  ASC IgG1 3-30 4 AKEGSKGWLQSSCYFDY 0 3-25 2 QSADSSGTYQV 2 0.1   
HK CV07-102  ASC IgG1 1-18 6 ARDLARVGWTWWYYYYGMDV 2 2-30 1 MQGTHWPRT 0 n.exp.   
HL CV07-103  ASC IgM 3-23 4 AKVYGSNTHTPVDY 5 2-8 2 SSYAGSNNVV 4 0.09   
HK CV07-104  ASC IgG1 3-7 6 ARDAARYYGMDV 24  1-39 2 QQSYSTPRT 10  0.09   
HK CV07-107  ASC IgG3 3-23 6 AKDRRTMIVVVITNKYYYGMDV 0 1-5 4 QQYNSYPLT 0 0.11   
.CC-BY-NC 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a






















































































































































HL CV07-108  ASC IgM 3-15 4 TTDADTSPVV 4 4-69 3 QTWDTGIRV 7 0.08   
HK CV07-110  ASC IgM 3-48 4 ARSLRMG 7 3-20 1 HQYGSIPRT 12  n.exp.   
HK CV07-113  ASC IgA1 4-59 6 ARASFKMGTNYHYGMDV 13  1-27 3 QNYNSVPFT 12  0.08   
HK CV07-114  ASC IgG1 1-2 4 TTLTAVVTPLGY 40  2-30 1 MQGTHWPRT 1 0.07   
HL CV07-118  ASC IgM 3-15 3 TTDEQRNYCTSPNCRGGAFDI 7 4-69 3 QTWGTGIRV 7 n.exp.   
HK CV07-121  ASC IgG1 4-39 5 MRQGDWNYSYYFDA 35  2-30 4 VQGTLWPLT 12  n.exp.   
HK CV07-127  ASC IgA1 4-39 6 ARHPLALITIFGVSRQYGMDV 0 1-12 1 QQANSFPWT 1 0.1   
HL CV07-128  ASC IgG2 3-30-3 4 ARELGTSGTLDS 23  2-14 3 LSHSTFTTPQWV 21  0.08   
HL CV07-129  ASC IgG1 3-48 3 ASIASYDYVWGTNRPNDAFDI 17  2-23 1 CSYGGPRNLYV 15  0.09   
HL CV07-132  ASC IgM 4-4 4 ARDRQYRGSDYNYYFDY 3 1-44 3 ATWDDSLNGRV 5 0.09   
HK CV07-133  ASC IgG2 4-39 4 ARHQRPVTTFIDY 29  3-15 3 QHYKDWPPFFT 19  0.08   
HK CV07-134  ASC IgG1 3-23 6 AKVMRDDFWSGYYNDYYYGMDV 6 3-20 2 QQYGRT 0 0.09   
HK CV07-136  ASC IgG1 4-59 6 ARDNYSSRRYYYYYGMDV 0 3-20 1 QQYGSSPTWT 0 0.10   
HL CV07-137  ASC IgM 4-30-4 5 ARLSMTTVTRGNWFDP 0 1-47 3 AAWDDSLSGWV 0 0.10   
HK CV07-138  ASC IgA2 3-23 2 VKDFPFGGCTSTTTNCDLFFAL 21  2-24 1 MQATQFPRA 11  n.exp.   
HK CV07-139  ASC IgG2 4-59 5 AGYLRNDNLDP 11  3-11 4 QQRSDWPLT 9 n.exp.   
HK CV07-140  ASC IgA1 3-64 4 AREYYGLLTGYYLDL 19  1-39 1 QQSYSIPWT 24  0.08   
HK CV07-143 7-3 ASC IgG1 3-23 4 AKEFSIGWGLFDS 17  3-11 5 QQRNNWPVT 13  n.exp.   
HK CV07-147  ASC IgG1 1-2 6 ARDLYYDILTGYYMPMDV 4 3-11 5 QQRGNWPPIT 4 n.exp.   
HK CV07-151  ASC IgG1 1-58 3 AADPGGVGYCSGGSCYRAFDI 1 3D-15 4 QQYNNWPPALT 0 0.09   
HL CV07-152  ASC IgG1 1-69 3 ARLRVPLTAHDAFDI 0 1-40 3 QSYDSSVGV 3 0.09   
HL CV07-154  ASC IgG1 1-69 6 ARAYCSGGSCYSYYYGMDV 2 3-1 2 QAWDSSTA 0 0.11   
HK CV07-155  ASC IgM 4-59 6 ARVPREWLSPLYYG 2 1-5 1 QQYNSYQWT 0 0.09   
HL CV07-156  ASC IgG1 3-9 4 VKDNARTRRGSFDY 15  2-23 1 CSYAGSNTYV 13  0.09   
HL CV07-159  ASC IgG2 3-48 3 AREGELSNYDAFDI 18  2-11 1 CSYAGTHSYV 9 0.08   
HK CV07-161  ASC IgG1 3-30 4 AKEGSKGWLQSSCYFDY 1 2-28 5 MQAFEPPAIT 40  0.12   
HK CV07-163  ASC IgM 3-33 4 ARDWAVAGNFDY 14  3-20 5 QQYGASPPTT 7 0.09   
HL CV07-164  ASC IgA1 1-46 4 ARDGSHWDFDY 22  2-14 3 SSYVSSDAWV 4 0.09   
HL CV07-165  ASC IgM 3-53 4 ARRAASGWNFDY 9 2-23 3 CSYLGSATYV 19  n.exp.   
HK CV07-166  ASC IgG1 1-18 6 ARDTWDIVIVPAASAYYGMDV 21  2-28 2 MQALQTHT 1 n.exp.   
HK CV07-172  ASC IgM 3-15 4 TTDRTYDYVWGSYRYRDY 0 1-39 1 QQTFSSPPWT 27  0.07   
HK CV07-173  ASC IgM 3-30 6 SKGFLEWLLRRYYYGMDV 3 1-9 3 QQLNSYPFT 0 0.07   
HK CV07-176  ASC IgA1 5-51 6 ARHFGGSGSYYNGHWIPAYYYHGMDV 7 2-28 4 MQARQTPPLT 4 n.exp.   
HL CV07-176  ASC IgA1 5-51 6 ARHFGGSGSYYNGHWIPAYYYHGMDV 7 2-8 2 SSYAGSTNLV 4 n.exp.   
HK CV07-178  ASC IgG2 4-31 3 ARDRTMVVWNAFDI 17  1-39 1 QQSHSPSRT 13  0.18   
HL CV07-179  ASC IgA1 3-7 5 ARESRLGIAIFDRRLRSWFGA 0 2-14 1 SSYTSSSTRV 0 n.exp.   
HK CV07-180  ASC IgM 3-15 4 TTQHYDFWSGNYKPFAF 12  2-28 5 MQALQTLT 3 0.11   
HL CV07-181  ASC IgA1 3-33 4 ARDEAAEYYFDY 1 3-25 3 QSADSSGTFWV 1 0.11   
HK CV07-183  ASC IgG1 3-30 4 AKEGSKGWIQNSCYFDY 12  4-1 1 QQYYSTPPT 3 n.exp.   
HK CV07-185  ASC IgA1 3-23 4 VKDPNWANGY 30  2-30 4 VQGTHWPLT 16  n.exp.   
HK CV07-186  ASC IgA1 1-46 4 AKGRSTIFGVIVNQGDCYDY 9 1-27 4 QKYNSAPLT 4 0.10   
HK CV07-189  ASC IgG1 3-23 4 AKDPHFDFWSGNYFDY 5 1D-12 4 QQANSFPLT 0 0.06   
HK CV07-190  ASC IgM 4-31 3 ARDRGVTIFGVVIIDAFDI 1 3-20 4 QQYGSSPLT 0 0.05   
HK CV07-191  ASC IgG1 1-18 6 SREGDLTIFGSVTNAYYYFGMDF 3 1-39 5 QQSYSTPIT 1 n.exp.   
HL CV07-196 7-1 S1-MBC IgM 1-2 4 ARDLGIGVAGNLDH 4 2-8 3 SSYAGSNNWV 2 2.06 ++ >250 
HK CV07-199  S1-MBC IgM 4-59 5 ARDRDSSGWYPNWFDP 2 1D-16 1 QQYNSYPRT 0 0.07   
HL CV07-200 7-2 S1-MBC IgG1 1-2 6 ARGPFYYDNSGTLGGLDV 5 2-14 1 SSYTSSSTYV 1 8.57 ++ 25 
HL CV07-201 7-4 S1-MBC IgM 1-2 6 ATDRLVNTGVYTTGSMDV 8 2-23 1 CSYGGSSDYV 2 4.03 ++ >250 
HK CV07-202  S1-MBC IgG1 3-53 6 ARDLYYYGMDV 4 1-9 4 QQLNNYSVT 2 8.87 ++ 25-250 
HL CV07-203  S1-MBC IgM 1-2 6 ARKQQPSSLSYYYYGMDV 1 1-40 3 QSYDSSLSGSWV 3 0.06   
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HL CV07-204  S1-MBC IgM 4-39 6 ALCGYSYGSNYYYYGMDV 0 6-57 3 QSYDSSIWV 2 0.09   
HK CV07-205  S1-MBC IgM 3-23 4 AKEYGYDSSGSGGDY 0 1-39 1 QQSYSTPNT 0 0.07   
HL CV07-205  S1-MBC IgM 3-23 4 AKEYGYDSSGSGGDY 0 2-23 3 CSYAGSSTWV 2 n.exp.   
HK CV07-206  S1-MBC IgM 1-2 6 AREGYYDFWSGYYTVYYYGMDV 0 1-5 1 QQYNSYWT 9 n.exp.   
HL CV07-206  S1-MBC IgM 1-2 6 AREGYYDFWSGYYTVYYYGMDV 0 2-14 3 SSYTSSSTRV 1 3.98 ++ 250 
HL CV07-208 7-2 S1-MBC IgM 1-2 6 ARGPFYYDSSGTLGGMDV 3 2-14 1 SSYTSRNTYV 5 n.exp.   
HK CV07-209  S1-MBC IgG1 3-11 4 ARDGVIPPRFDY 2 1-33 4 QQYDNLPLT 1 12.06 ++ <25 
HL CV07-210  S1-MBC IgM 3-21 4 VSSGNYRFHY 8 2-14 1 SSYMSSSTPYV 4 0.18   
HL CV07-213 7-5 S1-MBC IgM 1-8 4 ARGPSWNGYYYYFDY 6 1-44 2 ASWDDRLNGVV 7 0.1   
HK CV07-214  S1-MBC IgG1 6-1 3 AREENAFDI 0 3-15 2 QQYSNWLLYT 4 7.69 ++ >250 
HK CV07-215  S1-MBC IgM 3-48 3 AREGHAFDI 2 3-20 1 QQYGSSPSWT 1 0.08   
HK CV07-216  S1-MBC IgM 3-7 4 VAWGTTPLGTSENN 16  2-30 2 MQHTHWPHT 11  0.08   
HL CV07-217 7-5 S1-MBC IgM 1-8 4 ARGPSWNGYYYYFDY 6 1-44 2 ASWDDSLNGVV 8 0.12   
HL CV07-218  S1-MBC IgM 3-23 4 AKRMGGNRFNPPVEY 12  1-40 3 HSYDSSLSASV 6 n.exp.   
HK CV07-219  S1-MBC IgG2 3-11 6 ARDGIGQLWDDSYYYGLDV 15  2-30 2 MQGAHWPPYT 10  3.68 ++ >250 
HL CV07-221 7-4 S1-MBC IgM 3-30 6 AKKAGYSSGWYTDYYYNGMDV 1 1-40 3 QSYDSSLRGV 4 0.15   
HL CV07-222  S1-MBC IgG1 1-2 3 ARGPYYYDSSGSLGAFDI 5 2-23 1 CSYAGGSTSYV 2 12.03 ++ <25 
HL CV07-223 7-5 S1-MBC IgM 1-8 4 VRGPSWNGYYYYFDY 6 1-44 2 ASWDDSLNGVV 3 0.08   
HL CV07-224  S1-MBC IgM 5-51 6 ARLGPYYSSSSNGMDV 2 2-23 3 CSYAGSSTRV 3 0.08   
HK CV07-225  S1-MBC IgG1 4-31 6 ARDTPPGYNWNYGPYGMDV 9 3-15 2 QQYNNWPPGYT 4 4.78 ++ >250 
HL CV07-226  S1-MBC IgM 3-30 6 AKKAGYSSGWYTDYYYNGMDV 1 2-8 3 SSYTASNRG 41  n.exp.   
HL CV07-230  S1-MBC IgM 3-9 4 AKEISGYYFDY 7 4-69 3 QTWGTGIHWV 14  0.08   
HL CV07-231 7-4 S1-MBC IgM 3-30 6 AKKAGYSSGWYTDYYYNGMDV 1 1-40 3 QSYDSSLRGV 4 0.07   
HL CV07-235  S1-MBC IgM 3-23 6 AKSTYGDYYYYYGMDV 7 2-14 3 NSYTSNSSLGV 8 6.16 ++ >250 
HK CV07-236  S1-MBC IgM 3-53 4 AREYSSGWYDY 0 3-15 4 QQYNNWPLT 3 0.09   
HL CV07-237 7-2 S1-MBC IgA1 1-2 6 ARGPFYYDSSGTLGGMDV 3 2-14 1 SSYTSSSTYV 0 5.58 + n.t. 
HL CV07-238  S1-MBC IgM 1-8 6 ARTNWNYYYYYYGMDV 0 1-44 1 AAWDDSLNGYV 2 0.09   
HL CV07-239  S1-MBC IgM 4-34 3 ARGRWYHDNNGYRSDAFDV 17  1-44 3 AAWDDSLNEV 9 0.07   
HL CV07-241  S1-MBC IgM 3-74 4 ITSMFNNGFY 7 2-11 2 SSYAGSYTV 7 0.08   
HL CV07-242  S1-MBC IgM 3-15 5 TTLWRLDP 46  7-46 3 LLTHTDSRV 11  n.exp.   
HL CV07-249 7-1 S1-MBC IgM 1-2 4 ARDLGIGVAGNLDH 1 2-8 3 SSYAGSNNWV 3 2.87 + n.t. 
HL CV07-250  S1-MBC IgG1 1-18 6 AGSDNYGFPYNGMDV 17  2-8 2 SSYAGNNDFV 16  8.27 ++ 25 
HK CV07-251 7-3 S1-MBC IgM 3-23 4 AKEFSIGWGLFDY 9 3-11 5 QQRNNWPVT 8 8.79 ++ 25-250 
HK CV07-252  S1-MBC IgG1 1-46 6 ARDKHWNNANYYYYGMDV 1 1-5 4 QQYNSYL 2 6.03 ++ >250 
HL CV07-254  S1-MBC IgM 1-2 4 ARDQGGAALVGHSNY 10  2-23 2 CSYAGSSTWV 3 6.71 ++ >250 
HL CV07-255  S1-MBC IgG1 1-2 4 ARDSRFSYVNGEFDY 3 2-23 3 CSYAGHSTWV 5 9.54 ++ 25 
HL CV07-262  S1-MBC IgG1 1-2 6 ARVGWYDFGTPGDYYYYYGMDV 6 2-23 1 CSYAGTSTFV 3 10.2 ++ < 25 
HK CV07-263  S1-MBC IgG1 1-2 6 ADSGYWGSHYYYGMDV 3 2D-29 1 MQSIQLPLT 0 7.87 ++ 25-250 
HL CV07-264 7-1 S1-MBC IgA2 1-2 4 ARDLGIGVAGNLDH 1 2-8 3 SSYAGSNNWV 2 7.08 ++ 250 
HK CV07-265  S1-MBC IgG1 3-48 6 ARRRYSSSWYYYYGMDV 2 1-9 4 QQLNSYPLT 0 6.41 - n.t. 
HL CV07-266 7-4 S1-MBC IgG1 1-2 6 ATDRLVNTGVYTTGSMDV 8 2-23 1 CSYGGSSDYV 2 4.62 ++ >250 
HL CV07-267 7-6 S1-MBC IgA1 1-2 6 ARVFGPGLDCSSTSCYTYGMDV 2 2-23 3 CSYAGSSSWV 1 8.47 ++ 250 
HL CV07-270  S1-MBC IgG3 3-11 5 ARARGSSGWYRIGTRWGNWFDP 2 2-14 2 SSYTSSSNVV 0 8.53 ++ 25-250 
HL CV07-271  S1-MBC IgA1 1-2 6 ARVPFAYCSSTSCDRGTPYYYYYGMDV 0 2-14 2 SSYTSSSTLV 3 8.28 ++ >250 
HK CV07-272  S1-MBC IgM 3-64 4 ARGLDNNGYYSGY 16  3-20 1 QQYGSSPRT 5 0.08   
HL CV07-274 7-7 S1-MBC IgM 1-2 4 ARDQKNDILTGLGDY 4 2-8 3 SSYAGSNNWV 1 3.97 ++ >250 
HL CV07-275  S1-MBC IgG1 3-66 4 ARDYYDSSGYYSSGGLGY 0 2-8 1 SSYAGSNNFV 0 4.51 ++ >250 
HL CV07-280 7-2 S1-MBC IgA1 1-2 6 ARGPFYYDSSGTLGGMDV 2 2-14 1 SSYTSSSTYV 0 7.29 ++ 25-250 
HL CV07-281 7-2 S1-MBC IgM 1-2 6 ARGPFYYDSSGTLGGMDV 2 2-14 1 SSYTSSSTYV 0 5.07 + n.t. 
HL CV07-283 7-2 S1-MBC IgA1 1-2 6 VRGPFYYDSSGPLGGMDV 7 2-14 1 SSYTSSSTYV 2 9.89 ++ 25 
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HL CV07-284  S1-MBC IgM 5-51 6 ASGGDYPYGMDV 5 1-44 3 AAWDDSLSAWV 1 0.87 ++ >250 
HL CV07-285 7-2 S1-MBC IgA1 1-2 6 ARGPFYYDNSGTLGGLDV 5 2-14 1 SSYTSSSTYV 1 9.3 ++ 25 
HL CV07-286  S1-MBC IgG1 3-9 6 AKGGRYCSGTNCYEYYFFAMDV 8 2-8 2 SSYAGSNNNVV 3 0.09   
HK CV07-287  S1-MBC IgG1 1-58 3 AAPYCSSTNCYDAFDI 0 3-20 1 QQYGSSPWT 0 9.25 ++ 25-250 
HK CV07-289  S1-MBC IgM 1-2 6 ARGAAMVTGYTYYYGLDV 3 3-20 5 QQYGSSPIT 2 0.07   
HL CV07-290 7-7 S1-MBC IgM 1-2 4 ARDQKNDILTGLGDY 0 2-8 3 SSYAGSNNWV 0 3.02 ++ >250 
HL CV07-292 7-7 S1-MBC IgM 1-2 4 ARDQKNDILTGLGDY 3 2-8 3 SSYAGSNNWV 0 7.92 ++ 250 
HK CV07-293  S1-MBC IgM 3-11 6 ARCNGGGACFYGMDV 10  4-1 5 QQYYSTLT 3 0.07   
HL CV07-293  S1-MBC IgM 3-11 6 ARCNGGGACFYGMDV 10  2-14 3 SSYTISSTWV 4 0.07   
HL CV07-294 7-2 S1-MBC IgM 1-2 6 ARGPFYYDSSGTLGGMDV 2 2-14 1 SSYTSSSTYV 0 5.69 ++ >250 
HL CV07-297  S1-MBC IgM 3-53 4 ARRSASGWNFDY 13  2-8 3 SSYAGSNNLV 8 0.08   
HL CV07-299  S1-MBC IgM 5-51 4 ATSHGYSGYELGY 9 2-14 3 SSYTSSSTVWV 29  n.exp.   
HK CV07-301  S1-MBC IgG1 1-2 6 ARVDTTGTTFWLYYYYGMDV 2 2D-29 3 N/A 0 0.17   
HL CV07-301  S1-MBC IgG1 1-2 6 ARVDTTGTTFWLYYYYGMDV 0 2-23 3 CSYAGSSTWV 2 n.exp.   
HK CV07-302  S1-MBC IgA1 3-9 6 AKDKGPYYYYGMDV 0 2D-29 1 MQSIQLPQT 0 1.51 ++ 250 
HL CV07-303 7-1 S1-MBC IgM 1-2 4 ARDLGIGVAGNLDH 4 2-8 3 SSYAGSNNWV 3 4.71 ++ 250 
HL CV07-304 7-6 S1-MBC IgA1 1-2 6 ARVFGPGLDCSSTSCYTYGMDV 1 2-23 3 CSYAGSNSWV 2 8.08 ++ >250 
HL CV07-305 7-1 S1-MBC IgM 1-2 4 ARDLGIGVAGNLDH 2 2-8 3 SSYAGSNNWV 2 0.93 ++ >250 
HK CV07-306  S1-MBC IgA1 1-2 4 ARGTLYYDILTGSPNPPKLDY 0 1-39 1 QQSYSTPWT 0 8.25 ++ 250 
HL CV07-307 7-2 S1-MBC IgA2 1-2 6 ARGPFYYDNSGTLGGLDV 5 2-14 1 SSYTSSSTYV 1 9.27 ++ 25 
HL CV07-309 7-2 S1-MBC IgM 1-2 6 ARGPFYYDNSGTLGGLDV 5 2-14 1 SSYTSSSTYV 1 8.62 ++ 25-250 
HL CV07-310 7-2 S1-MBC IgA1 1-2 6 ARGPFYYDSSGTLGGMDV 3 2-14 1 SSYTSSSTYV 0 5.11 + n.t 
HL CV07-312  S1-MBC IgM 1-2 6 ARIPIFGVVSTPGQYYYYGMDV 6 2-14 3 ISYTSSSTWV 1 0.18   
HL CV07-313 7-4 S1-MBC IgA1 1-2 6 ATDRLVNTGVYTTGSMDV 9 2-23 1 CSYGGSSDYV 2 0.09   
HK CV07-315  S1-MBC IgG1 3-9 6 AKDFLWDLHPPRYYGMDV 0 1-39 2 QQSYSTHA 1 0.16   
HL CV07-315  S1-MBC IgG1 3-9 6 AKDFLWDLHPPRYYGMDV 0 1-51 3 GTWDSSLNGV 1 11.4 ++ 25 
HL CV07-316 7-2 S1-MBC IgA1 1-2 6 ARGPFYYDSSGTLGGMDV 2 2-14 1 SSYTSSSTYV 1 3.12 + n.t 
HL CV07-317 7-7 S1-MBC IgM 1-2 4 ARDQKNDILTGLGHY 0 2-8 3 SSYAGSNNWV 0 2.53 ++ >250 
HK CV07-319  S1-MBC IgM 1-2 5 ARGPFFFEVVVAEGFGWFDP 28  3-15 5 QQYNNWPPIT 1 n.exp.   
HL CV07-319  S1-MBC IgM 1-2 5 ARGPFFFEVVVAEGFGWFDP 28  2-8 1 SSYAGSNVYV 0 n.exp.   
HL CV07-323 7-6 S1-MBC IgA1 1-2 6 ARVFGPGLDCSSTSCYTYGMDV 0 2-23 3 CSYAGSSSWV 1 7.39 ++ >250 
HL CV07-324 7-2 S1-MBC IgA1 1-2 6 ARGPFYYDSSSTLGGMDV 4 2-14 1 SSYTSSSTYV 3 11.02 ++ 25-250 
HK CV23-101  S1-MBC IgM 3-30 4 ARDWEYYGSGTKAFDY 9 1-13 4 QHFNSYPLT 9 4.33 ++ >250 
HL CV23-103  S1-MBC IgA1 1-2 4 N/A 47  2-14 2 SSYTRSTAVV 19  n.exp.   
HL CV23-113  S1-MBC IgM 5-51 4 ATTRGYSDYEFAY 11  2-8 3 SSYAGSNNFPWV 3 n.exp.   
HK CV23-114  S1-MBC IgM 4-31 5 ARDLGPRSDFGSGSGVGVIDP 10  3-15 1 QQYHNWPPWT 5 n.exp.   
HL CV23-115  S1-MBC IgM 1-2 3 ARGYYDILIGYATTHDAFDL 8 2-14 3 SSYTDSSTWV 6 n.exp.   
HK CV23-116  S1-MBC IgM 3-21 6 ARASLVTMVRGAGNYMDV 0 3-11 5 QQRSNWPLT 0 0.11   
HL CV23-116  S1-MBC IgM 3-21 6 ARASLVTMVRGAGNYMDV 0 2-23 3 CSYAGSRV 2 0.09   
HL CV23-121  S1-MBC IgM 1-2 4 ARELGSWDGRFDY 0 2-23 3 CSYAGSSTWV 0 0.10   
HK CV23-126  S1-MBC IgM 4-59 6 ARDTTSYCSGGSCYYNYGMDV 7 2-28 3 MQALQTPRT 3 0.07   
HL CV24-198 24-1 S1-MBC IgA1 1-2 3 ARDLAYSMVRGISGI 7 2-23 3 CSYAGSNTWV 7 5.48 ++ 250 
HL CV24-201 24-1 S1-MBC IgA1 1-2 3 ARDLAYSMVRGISGI 7 2-23 3 CSYAGSNTWV 9 5.79 ++ >250 
HK CV24-220  S1-MBC IgA2 3-48 4 ARDRGSGWSLDESYFDH 15  1-39 2 QQSKSIPYT 17  n.exp.   
HL CV24-223 24-5 S1-MBC IgM 4-39 4 ARLRWLRGEFDY 0 6-57 3 QSYDSSTYWV 0 8.83 ++ >250 
HL CV24-226 24-5 S1-MBC IgM 4-39 4 ARLRWLRGEFDY 0 6-57 3 QSYDSSTYWV 0 8.77 ++ >250 
HL CV24-236  S1-MBC IgM 3-49 4 IRGGYGGNSGFDY 5 1-51 2 GTWDSSLSAVV 3 0.15   
HL CV24-243  ASC IgM 3-7 4 ARLYSGNYFDY 6 4-69 3 QTWDTAIWV 14  n.exp.   
HK CV24-247  ASC IgA1 3-48 5 ARGFYDILTGYYSFHFDL 16  1-5 1 QQYNTYWT 7 0.35   
HK CV24-248 24-2 ASC IgG1 3-33 6 ARREGVADYYYYYGMDV 8 1-6 1 LQVYNYPWT 6 0.09   
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HL CV24-249  ASC IgG1 1-18 6 AREYDYSNPNYYYYYGMDV 0 3-27 3 YSAADNMGV 1 0.08   
HK CV24-252  ASC IgG1 3-74 6 VRVSGPFHDYFLYAMDV 19  3-20 1 QHYSAATWT 14  0.09   
HL CV24-253 24-3 ASC IgA1 1-2 4 ARVFHGVITPFDY 12  5-37 2 MIWPSSAVV 7 0.07   
HK CV24-255  ASC IgG1 4-34 4 ARGRLGFEELFRGVFFYYFDY 21  1-39 2 QQTFNSPRT 22  0.07   
HK CV24-256 24-4 ASC IgM 3-49 5 TRAQEEKITMIRRIISWFDP 5 3-20 5 QQYGSSPIT 6 0.1   
HL CV24-260  ASC IgG1 4-59 6 ARLLKSCTGGICQTYFYYAMDV 21  1-40 1 QSYDGSLSESAV 20  0.1   
HK CV24-262  ASC IgA1 4-31 4 ARGTTYTIFGVVISPFDY 0 3-20 4 QQYGSSPLT 0 0.09   
HK CV24-265  ASC IgG1 4-34 5 ARGAPGT 30  1-5 2 QHYSTFPYT 15  0.1   
HK CV24-268  ASC IgG1 3-9 4 TTGYCRSNNCLTFYAF 20  1-39 2 QQSYRAPVT 13  0.08   
HL CV24-269  ASC IgM 4-31 6 ARDYFGRSGSGSSLYYYYGMDV 0 3-1 2 QAWDSSTV 0 5.39 - n.t. 
HK CV24-271  ASC IgG1 3-21 4 ARVAAAGQKYYFDY 0 1-9 4 QQLNS 0 0.12   
HL CV24-275  ASC IgG1 3-30 6 AKVANVFMLYPRGSWGMDV 14  1-47 3 AAWDDSLSGWV 14  0.09   
HK CV24-280  ASC IgG1 3-48 6 AAGSSTSPSPV 0 3-15 1 QQYNNWPRT 0 0.16   
HK CV24-282  ASC IgG1 3-23 6 AKDRGRRLTHLGVAPDV 23  1-39 2 QQSYTTPYT 19  0.15   
HK CV24-283  ASC IgM 3-66 4 CGGYGSSWYLDY 20  3-11 2 QQRSNWPYT 10  0.15   
HL CV24-284  ASC IgG1 4-31 4 ARGGLSSRNGGNRSYSSSSFPLGRQDY 0 2-14 1 SSYTSSSTLYV 1 0.15   
HL CV24-285  ASC IgM 5-51 4 ARFLSFVTSPTRYDY 6 2-14 1 SSYTSSSTLV 8 0.14   
HK CV24-286  ASC IgG1 1-69 3 ARHLPLSGYYAFDV 22  3-20 2 QQYGSSPYT 13  0.19   
HK CV24-287  ASC IgM 3-23 3 AKDRSGGILAGGSGGALDI 26  1-5 1 QQYSSYSRT 14  0.16   
HL CV24-290  ASC IgG1 4-39 4 ARASEDISLERAYNYGLTIDF 10  3-9 2 QVWDSSTVV 6 0.16   
HL CV24-293  ASC IgA1 3-7 6 ARENYDSSGYYYAYYYYGMDV 0 3-25 1 QSADSSGTYV 3 n.exp.   
HK CV24-294  ASC IgM 3-9 4 ARGDLGIRYFDY 5 3-15 5 QQYNNWPPIT 1 n.exp.   
HL CV24-294  ASC IgM 3-9 4 ARGDLGIRYFDY 5 2-23 3 CSYAGSSTWV 2 n.exp.   
HK CV24-296  ASC IgG3 1-18 1 N/A 11  4-1 2 QQYHSTPPA 4 n.exp.   
HL CV24-296  ASC IgG3 1-18 1 N/A 11  2-23 3 CSYAGSSTWV 2 n.exp.   
HK CV24-298  ASC IgG1 3-33 3 ARGWGGDGYTVDAFDV 19  2-28 2 MQALQPPYI 9 n.exp.   
HK CV24-301  ASC IgG1 1-46 5 ARSLYSGSYGAYNWFDP 19  3-11 4 LQRINWLT 13  n.exp.   
HK CV24-309  ASC IgG1 4-61 6 AREQVLDPGLYYGIDV 29  1-39 2 QQSYSTHT 1 n.exp.   
HL CV24-309  ASC IgG1 4-61 6 AREQVLDPGLYYGIDV 29  3-1 2 QAWDSDTVI 23  n.exp.   
HL CV24-310 24-3 ASC IgG1 1-2 4 ARVFHGVITPFDF 19  5-37 2 MIWPSSDVV 4 n.exp.   
HL CV24-311  ASC IgG1 1-2 4 ARGADIFITIFGVVIKENDY 0 2-18 2 SSYTSSSTLV 2 n.exp.   
HL CV24-314  ASC IgM 3-30 4 ARGKNYGYSDDDLFQHFDY 3 7-43 3 LLHYGSSQLGV 12  n.exp.   
HK CV24-316  ASC IgG1 1-69 6 ARALGLSGHGMDV 29  1-39 2 QHSYSTPHT 17  n.exp.   
HL CV24-317  ASC IgG1 4-4 3 AKESWLELWLQGAGFDI 16  2-11 2 CSYGGSYTFVV 12  n.exp.   
HL CV24-319  ASC IgG1 1-46 6 ARDLWMEYEYNDSGIQKTADQGMDV 16  3-1 3 QAWDINTVV 17  n.exp.   
HK CV24-321  ASC IgM 3-33 3 ARDMVRGPNDASDI 10  1-12 4 QQANSFPLT 4 n.exp.   
HL CV24-322  ASC IgG1 4-39 4 ARQRTHTIFGVVVHFDY 1 3-25 1 QSADSSGTYDV 3 n.exp.   
HK CV24-323 24-4 ASC IgM 3-49 5 TRAQEEKITMIRRIISWFDP 5 3-20 5 QQYGSSPIT 6 n.exp.   
HK CV24-325 24-4 ASC IgM 3-49 5 TRAQEEKITMIRRIISWFDP 5 3-20 5 QQYGSSPIT 8 n.exp.   
HK CV24-329  ASC IgM 3-33 3 ARDMVRGPNDASDI 10  3-15 5 QQYNNWPPVT 3 n.exp.   
HK CV24-330 24-4 ASC IgM 3-49 5 TRAQEEKITMIRRIISWFDP 5 3-20 5 QQYGSSPIT 11  n.exp.   
HL CV24-331  ASC IgG1 3-23 6 AKEVPDIIVVAVAVGMDV 21  1-47 2 ASWDDSLSGVL 12  n.exp.   
HL CV24-332  ASC IgG1 1-2 6 ARETRETYYDILTGYPFYYYFGMDV 9 1-51 2 GTWDGSLSAAV 11  n.exp.   
HL CV24-333  ASC IgM 3-15 4 SSDLPKWGSGMADY 13  8-61 3 VLYMGSDIWA 12  n.exp.   
HK CV24-336 24-4 ASC IgM 3-49 5 TRAQEEKITMIRRIISWFDP 5 3-20 5 QQYGSSPIT 8 n.exp.   
HK CV24-344 24-2 ASC IgG1 3-33 6 ARREGVADYSYSCGMDV 10  1-6 1 LQVYNYPWT 11  n.exp.   
HK CV24-346  ASC IgG1 1-69 3 ARSDDSSGYYYLKEENDAFDI 0 2-30 2 MQGTHWREYT 1 n.exp.   
HL CV24-347  ASC IgG3 1-2 6 ARDRLYCSSTSCYTPYYYYYYGMDV 0 3-25 3 QSADSSGTYGV 3 n.exp.   
HL CV38-102  S1-MBC IgG1 3-23 2 AKVETRGVGFDL 1 3-1 2 QAWDSSTVV 1 8.7 - n.t. 
HK CV38-103  S1-MBC IgA1 3-11 4 ARDWNLSGYYGGGR 1 1-16 4 QQYNSYPLT 0 5.84 ++ >250 
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HK CV38-105  S1-MBC IgG1 3-74 6 ARQRVARRRGFGESPFYYGLDV 22  1-6 1 LQNYNFPRT 7 0.26   
HL CV38-107 38-1 S1-MBC IgA1 1-2 4 ARDGAQYILTGDFDY 0 2-8 1 SSYAGSNNYV 0 0.58 + n.t. 
HK CV38-113  S1-MBC IgG1 3-53 4 ARGGRLADAAGDY 1 1-33 2 QQYDNLPSWT 1 11.47 ++ 25 
HK CV38-114  S1-MBC IgM 5-51 4 ARAGNDNSLDY 1 1-39 2 QQSYTTPYT 18  0.17   
HL CV38-114 38-4 S1-MBC IgM 5-51 4 ARAGNDNSLDY 1 9-49 3 GADHGSGSNFVQKV 1 8.13 ++ >250 
HL CV38-115  S1-MBC IgG1 3-7 5 ARDLYYYDSSGNGVNWFDP 3 1-40 1 QSYDSSLSGSYV 1 8.04 ++ n.t. 
HL CV38-117  S1-MBC IgG1 4-30-4 4 ARVTRIYGSGSYCFDY 0 2-23 2 CSYVGSSTFVV 2 9.55 ++ >250 
HK CV38-118  S1-MBC IgA1 4-59 4 ARAWSSSWYLDY 3 3-11 4 QQRSNWPPVT 0 0.51 + n.t. 
HL CV38-119  S1-MBC IgA1 4-4 4 ARAWNFDY 0 2-23 3 CSYAGSSNWV 1 5.56 ++ >250 
HL CV38-122  S1-MBC IgG1 3-23 3 AKVLDI 0 2-14 1 SSYTSSSTPYV 2 n.exp.   
HK CV38-124  S1-MBC IgG1 4-59 6 ATYYYDSSGYPYGMDV 1 1-9 3 QQLNSYPG 3 6.07 ++ >250 
HL CV38-125 38-4 S1-MBC IgG1 5-51 4 ARHQGYSSSSLGY 1 9-49 3 GADHGSGSNFVYM
V 
1 8.53 ++ >250 
HK CV38-127  S1-MBC IgG1 3-33 4 ARDPEIVVGGVDY 0 2-30 2 MQGTHWPYT 0 3.45 ++ >250 
HK CV38-128  S1-MBC IgA1 3-11 4 ARDWNLSGYYGGGR 0 1-39 2 QQSYTTPYT 18  0.15   
HK CV38-129  S1-MBC IgG1 4-31 3 ARDQGASASWDAFDI 0 3-20 4 QQYGSSLT 0 2.24 ++ >250 
HK CV38-131  S1-MBC IgA1 3-11 4 ARDHSVRFLEWLLPY 0 1-9 1 QQLNSYPWT 3 1.93 + n.t. 
HK CV38-132  S1-MBC IgG1 4-31 4 ARAERSITIFGVVTSAFDY 1 4-1 2 QQYYSTPYT 0 1.24 + n.t. 
HK CV38-134  S1-MBC IgG1 4-34 4 ASSGWYYPDY 3 3-20 4 QQYGSSPNT 0 7.98 ++ >250 
HL CV38-135  S1-MBC IgG1 3-23 3 AKVTGLGNAFDI 3 3-1 2 QAWDSSTVV 0 7.19 - n.t. 
HL CV38-136  S1-MBC IgG1 4-4 5 ARSSGRGRVVALGSFDP 1 2-23 3 CSYAGSSTWV 0 8.52 - n.t. 
HK CV38-139  S1-MBC IgG1 3-53 4 ARGHYDLFDY 3 1-9 3 QQLNSYPPGT 0 8.33 ++ 25-250 
HK CV38-140  S1-MBC IgA1 4-31 4 ARAYDSSGYYPDY 0 1-39 4 QQSYSTLT 0 2.56 ++ >250 
HK CV38-142  S1-MBC IgG1 5-51 4 ARIRGVYSSGWIGGDY 4 1-39 1 QQSYSTPRQWT 0 9.39 ++ 25 
HL CV38-143 38-1 S1-MBC IgM 1-2 4 ARDGAQYILTGDFDY 0 2-8 1 SSYAGSNNYV 0 2.30 + n.t. 
HK CV38-146  S1-MBC IgG1 1-69 5 ARAATYYYDSSGYTPNWFDP 1 1-39 2 QQSYSTLYT 0 2.17 ++ >250 
HL CV38-147  S1-MBC IgG1 3-9 4 AKDRRIAVAGTGEDYYFDY 4 3-21 2 QVWDSSSDQVV 1 11.7 ++ 250 
HL CV38-148  S1-MBC IgG1 3-66 4 ARSAPLVGAYSGIYFDY 2 9-49 2 GADHGSGSNFVV 1 7.26 ++ >250 
HK CV38-149 38-3 S1-MBC IgM 3-9 4 AKNRVAGTIFGVGPFDY 0 1-6 4 LQDYNYPLT 1 0.73 - n.t. 
HK CV38-150  S1-MBC IgG1 3-30 3 AKSQWLVLRHAFDI 0 2D-29 1 MQSIQLWT 0 11.04 - n.t. 
HL CV38-156  S1-MBC IgG1 4-59 4 ARFSQYYYDSSGYDFDY 0 2-23 3 CSYAGSSSWV 3 0.42   
HK CV38-158  S1-MBC IgM 3-15 6 TTDRWFGELFSAYYYYYGMDV 0 3-11 3 QQRSNWPPIFT 0 0.17   
HL CV38-159  S1-MBC IgG1 1-2 4 ARGNTVFWSGPPLDY 0 2-14 1 SSYTSSSTYV 0 4.27 + n.t. 
HL CV38-160  S1-MBC IgG1 3-23 3 AKVAGRGNAFDI 3 7-43 2 LLYYGGAL 3 n.exp.   
HK CV38-165  S1-MBC IgG3 4-4 4 ARRSLGNYDSSGYDH 1 3-15 5 QQYNNWPPAIT 1 5.09 - n.t. 
HL CV38-165  S1-MBC IgG3 4-4 4 ARRSLGNYDSSGYDH 1 1-44 1 AAWDDSLNGYV 0 0.15   
HL CV38-173  S1-MBC IgG3 3-30-3 4 ARDYGGYNYN 4 3-1 2 QAWDSSTVV 0 9.92 - n.t. 
HK CV38-177 38-3 S1-MBC IgG1 3-9 4 AKDMVVVAIFGVGPFDY 1 1-6 4 LQDYNYPLT 1 10.77 - n.t. 
HK CV38-179  S1-MBC IgM 5-51 3 ARQRRPPGKRVLTMIVVVYNDAFDI 1 1-33 3 QQYDNLLFT 0 n.exp.   
HL CV38-179  S1-MBC IgM 5-51 3 ARQRRPPGKRVLTMIVVVYNDAFDI 1 1-40 2 QSYDSSLSGSV 2 n.exp.   
HL CV38-180  S1-MBC IgG1 4-4 4 ARRAAAGPRPYDY 2 2-23 3 CSYAGFSTWV 6 n.exp.   
HK CV38-181  S1-MBC IgA1 1-2 3 ARDLGYSYLYGAFDI 1 3-11 4 QQRSNWPT 4 6.17 ++ >250 
HL CV38-182  S1-MBC IgA1 1-69 2 AKELGYSGYGAHRYFDL 3 1-40 2 QSYDSSLSGVV 0 11.73 ++ 250 
HL CV38-183  S1-MBC IgG1 3-53 6 ARGDGWDNYYYGMDV 0 1-40 2 QSYDSSLSGSV 2 11.06 ++ <25 
HK CV38-184  S1-MBC IgG1 4-39 5 ARGLGWFDP 0 1-NL1 2 QQYYSTPPRT 0 1.89 ++ 250 
HL CV38-186  S1-MBC IgG1 1-2 4 ARDQSPDILKSPFDY 1 2-23 3 CSYAGSSTFG 0 6.51 ++ 250 
HL CV38-193  S1-MBC IgA1 3-11 4 ARDISRNLHDFRPYYFDY 2 7-46 3 LLSYSGARV 1 1.53 + n.t. 
HL CV38-194  S1-MBC IgG1 4-59 3 ARHDVYSSGWYGEGAFDI 2 1-40 3 QSYDSSLSGSWV 3 0.09   
HL CV38-199  ASC IgG3 4-59 4 ARYYQDFDY 0 1-44 1 AAWDDSLNGPYV 1 0.07   
HK CV38-201  ASC IgG1 3-30 4 AKDIVLVPAAIPVPIFDY 2 3-11 5 QQRSNWPPT 1 0.07   
HL CV38-202  ASC IgG1 3-33 3 ARDSSQQQLAYAFDI 2 3-1 2 QAWDSSIVV 1 0.1   
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HL CV38-205  ASC IgG1 4-30-2 6 ARDHYPYYYYGMDV 0 6-57 2 QSYDSSTVV 1 0.09   
HK CV38-206  ASC IgA2 3-7 6 ARKGNAIDV 3 1-5 2 LQYNSYSWYT 1 0.08   
HL CV38-207 38-5 ASC IgA1 4-30-4 3 AKIRVRAGFRWAFDI 22  2-14 3 SSYTNTNTLV 20  0.09   
HL CV38-208  ASC IgM 4-39 2 AHQSGNSGPWYFDL 0 8-61 2 VLYMGSGIVV 1 0.08   
HL CV38-210  ASC IgG1 4-39 4 ARHVEPDYGGNSFDY 0 1-40 1 QSYDSSLSGYV 1 0.11   
HL CV38-211  ASC IgG1 3-9 6 AKDISNKWLRLTQPYSYYGLDV 3 2-8 1 SSYAGSNIPYV 7 0.08   
HL CV38-213  ASC IgG1 3-23 3 AKVLIRNGYDILTGYPYDAFDI 0 2-14 2 SSYTSSSTLV 0 3.15 + n.t. 
HL CV38-215  ASC IgA1 3-30-3 4 ARDGYSAYDFGY 20  8-61 3 VLFMGSGTWV 18  n.exp.   
HK CV38-217  ASC IgA1 4-30-2 4 ASGPAWELFDY 17  3-15 3 QSYHNWPL 15  0.10   
HK CV38-219  ASC IgA1 4-39 4 ARQMRIGTIVVVPAALDY 2 3-20 1 QQYYSSPWT 5 0.07   
HK CV38-221  ASC IgG1 3-66 4 ARGFGDYYFDY 4 3-20 2 QQLYT 1 10.74 ++ 25-250 
HK CV38-222  ASC IgG1 4-30-4 6 ARDPWQVTIFGVVIRYGMDV 0 1-9 2 QQLNSYPRT 3 0.09   
HL CV38-225  ASC IgM 3-11 5 ARDLWFGRYWGNWLDP 10  1-51 3 GTWDNSLSAAV 7 0.09   
HL CV38-227  ASC IgA1 3-66 6 ASEGRTTGTIVAYYYFAMDV 15  2-8 2 SSYAGRSNVV 15  0.09   
HK CV38-228 38-6 ASC IgA1 4-31 4 AREKGTGDYYLDY 16  3-15 1 QQYNSWPRA 17  0.08   
HL CV38-229 38-5 ASC IgA1 4-30-4 3 AKIRVRAGFRWAFDI 23  2-14 3 SSYTNTNTLV 20  0.09   
HL CV38-230  ASC IgG1 3-53 4 ARDNSSNWYYFDS 8 3-25 1 QSADSSGTYV 10  n.exp.   
HL CV38-231  ASC IgG1 3-33 6 ARDGLDDDYIWGSFKIRYYYMDV 1 2-8 3 SSYSGTTNFAQ 19  0.08   
HL CV38-232  ASC IgA1 3-23 4 ASGTYRLGDY 26  1-44 3 AAWDDSLDGPV 15  n.exp.   
HL CV38-233  ASC IgG1 4-4 5 VTGGRWRFDP 16  2-11 3 CSYAGTYTYWL 12  0.08   
HK CV38-235 38-2 ASC IgA1 3-23 4 VRDLSSSDPWYFDF 15  3D-20 1 QQYGDSPRT 11  n.exp.   
HK CV38-236  ASC IgG1 3-64 6 ARGGYEIVVVPDYYYYGMDV 0 3-20 4 QQYKD 0 5.74 - n.t. 
HK CV38-238 38-7 ASC IgM 3-30 6 AKDPLNCSSTRCYTAWIYYYYGMDV 0 2D-29 4 MQSIQLPLT 0 0.09   
HK CV38-240 38-7 ASC IgG1 3-30 6 AKDSVKGYSSGWYYYYYGMDV 0 2D-29 4 MQSIQLPLT 0 0.09   
HK CV38-242 38-2 ASC IgA1 3-23 4 ARDLSSSDPWYFDF 14  3D-20 1 QQYGDSPRT 11  0.08   
HK CV38-243  ASC IgM 3-21 4 ARDRSGWYRNLFDY 1 2-28 5 MQALQASIT 0 0.08   
HK CV38-245  ASC IgG2 3-49 3 TRDFDHADSFDI 24  2-28 2 MQALHTPRYT 9 0.09   
HK CV38-248  ASC IgG2 3-30 4 AKGFYDSGP 12  2-30 2 MQGTHWKT 3 0.10   
HL CV38-251  ASC IgA2 3-23 6 AKDQTVSFFYYGMDV 5 1-47 1 ATWDDSLSGYV 10  0.07   
HK CV38-252  ASC IgM 1-3 4 ARDNTNTWFGSIEY 36  4-1 3 QQNYATPLT 21  n.exp.   
HL CV38-255  ASC IgG2 3-9 4 VREATRGAHFDC 32  2-8 1 SSYVGFNNLDNFV 19  0.07   
HK CV38-257  ASC IgM 4-34 2 ARRIYYGDLGNWNFDL 24  1-16 4 QQYNSYPLT 20  n.exp.   
HL CV38-259  ASC IgG1 1-69 4 ATLGYCSGGSCFPTGVFGY 0 7-46 3 LLSYSGARSWV 1 0.05   
HK CV38-263 38-6 ASC IgA1 4-31 4 AREKGTGDYYLDS 21  3-15 1 QQYNSWPRA 21  0.09   
HK CV38-265  ASC IgG1 3-23 6 AKDGHSMVRGVTMWGEFYYYYGMDV 0 3-15 2 QQYNNWPPYT 0 0.1   
HK CV38-270  ASC IgG2 3-9 3 VRSRWQLTSSAFDM 33  1-9 4 QQLNKYPIT 25  n.exp.   
HK CV38-271 38-6 ASC IgA1 4-31 5 AREKGTGDYYLDP 22  3-15 2 QQYNSWPRA 21  0.09   
HL CV38-273  ASC IgG1 1-2 6 ARTYYYDSSGYRNYYYYGMDV 4 2-18 1 SLYTSSSTYV 0 0.18   
HK CV38-275  ASC IgG1 3-15 4 TTDRGNSITIFGVVIIDRPY 0 3-20 2 QQYGSS 0 n.exp.   
HL CV38-276  ASC IgA1 3-21 6 ARDEGSPGLDYYGMDV 1 2-14 2 SSYTSNTTLVV 4 0.08   
HL CV38-278 38-5 ASC IgA1 4-30-4 3 AKIRVRAGFRWAFDI 21  2-14 3 SSYTNTNTLV 22  0.08   
HL CV38-281  ASC IgG1 3-11 4 ARDMNYKYYYDSSGYPLLDY 0 1-44 3 AAWDDSLNGWV 0 0.15   
HK CV38-284  ASC IgA1 3-49 4 IRARYYYDSSATFDY 18  1-39 4 QQCYSLPST 18  n.exp.   
HL CV38-286  ASC IgA2 3-30 6 AKDASSPVYDFWSGYYNHLGMDV 0 3-21 3 QVWDSSSDQGV 2 0.11   
HK CV38-288  ASC IgM 3-66 6 ARDYTVTTGGVDGMDV 0 3-11 1 QQRSNWPPWT 0 n.exp.   
HK CV38-289  ASC IgA1 3-23 4 VSRAAVGQPEY 44)  1D-12 3 QQAYTLPRVT 35  n.exp.   
HK CV48-103  S1-MBC IgG1 3-49 6 SRFYDYWNTFGLLLGSGLTFYHMDV 22  4-1 1 QQYCYTPWT 13  0.07   
HL CV48-104  S1-MBC IgG1 1-69 5 ARDGQQLVRGWFDP 0 2-14 1 SSYTSSSTLYV 2 6.93 ++ >250 
HL CV48-107  S1-MBC IgG1 4-39 4 ASENDYGEHDY 0 4-60 2 ETWDSNTRKVV 1 0.1   
HL CV48-109  S1-MBC IgG1 3-30 4 VKGDTSAYWPSSLLIS 34  2-14 2 GSYATGSSPVV 17  0.10   
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HK CV48-110  S1-MBC IgA1 3-33 4 ARDARYSAYELPDYFFDL 17  1-5 1 QQYKGSSWAT 10  n.exp.   
HL CV48-113  S1-MBC IgG1 3-33 6 ARDGLDDDYIWGSFKIRYYYMDV 0 4-69 2 QTWGTGINVV 1 0.08   
HL CV48-119  S1-MBC IgA2 3-23 4 AKTDRHWNHCD 18  2-14 2 SSYTGSSTLVA 18  0.08   
HL CV48-123  S1-MBC IgM 1-3 4 ARNGGGLDQ 21  2-14 2 CSSTTSSTAV 12  n.exp.   
HK CV-X1-102  S1-MBC IgG1 1-69 6 ARSPRPLIVVAEDGMDV 1 3-20 3 QQYGSSPFT 1 6.81 ++ >250 
HL CV-X1-109  S1-MBC IgG1 1-2 4 ARGPLFWDTAMANFDY 0 2-14 3 N/A 4 0.12   
HK CV-X1-111  S1-MBC IgM 3-49 4 NRELHNSVVVGVMGY 17  4-1 2 HHYYSPPYA 7 0.16   
HK CV-X1-112  S1-MBC IgM 3-23 4 AKVGSGWYAFDY 16  3-15 1 QQYNKWPRT 5 0.09   
HL CV-X1-119  S1-MBC IgG1 4-59 6 ARDRIMPLSYYYYYGMDV 0 1-44 3 AAWDDSLNGWV 0 0.17   
HK CV-X1-126  S1-MBC IgG1 3-53 6 ARDLSEGGMDV 2 1-12 4 QQANGFPPL 2 11.78 ++ 25-250 
HK CV-X1-128  S1-MBC IgG1 5-51 6 ARTYDFWSGFDYYGMDV 3 3-11 3 QQRSNWPT 0 0.13   
HL CV-X1-131  S1-MBC IgG1 3-30 4 ARMATTYPEHDPSLY 2 3-21 3 QVWDSSSDHWV 2 10.74 ++ >250 
HK CV-X1-136  ASC IgM 4-31 5 AAWRGFAATGFDS 21  1-9 3 QQLKSYPLT 7 0.1   
HK CV-X1-137  ASC IgA1 1-8 3 ATEGTILTTMTAGAFDL 26  1-12 2 QQTDNFPYT 18  0.17   
HK CV-X1-140  ASC IgA1 1-69 4 ARFGGTSQSSGYYGFDN 23  2-28 2 MQPLQTPYT 11  0.08   
HL CV-X1-141  ASC IgG1 3-23 6 VTHDFPDWPPGGGMDV 18  6-57 3 QSYDWSNQGV 10  0.16   
HK CV-X1-142  ASC IgG2 1-18 4 STRGMAPHDY 28  1-39 1 HQTYDTWT 33  n.exp.   
HK CV-X1-143  ASC IgG1 3-11 4 ARDLGYSTRFDY 0 1-33 4 QQYDNLPLT 0 6.76 ++ >250 
HK CV-X1-145  ASC IgG1 5-51 4 AREDLTGPDY 8 2-30 2 MQGTHWPNT 1 0.16   
HL CV-X1-146  ASC IgG1 3-23 4 ANNYYDNSGPDY 30  6-57 3 QSNDGSPSWV 20  0.15   
HL CV-X1-150  ASC IgG1 5-51 4 ARHLVCGGSCYPFDY 0 3-21 3 QVWDSSSDHQV 1 0.33   
HL CV-X1-153  ASC IgG3 3-33 4 ARDWFWRLGGVDY 0 8-61 2 VLYMGSGLVV 2 0.16   
HL CV-X1-157  ASC IgA1 3-48 6 ATSYYDPSSAYSAHYAMDV 32  2-14 2 TSYTSLSPVV 20  0.09   
HK CV-X1-164  ASC IgG1 1-2 6 ARSFGGFGGNYGMDV 3 1-39 5 QQSYSTPIT 0 0.13   
HL CV-X1-165  ASC IgA2 3-48 4 ARDPIGTGSDY 13  1-51 2 GTWDSSLNAGV 9 0.13   
HK CV-X1-167  ASC IgA2 3-74 5 ARAHSTTLYGWFDP 17  3-20 1 QHYVSSPLT 13  0.09   
HL CV-X1-171  ASC IgA2 4-34 4 ARGFRKGSTFN 13  2-14 3 SSYTTSNTRE 15  0.09   
HK CV-X1-172  ASC IgG1 3-48 6 ARDRLTIFGVAIDYYGMDV 0 1-12 4 QQANSFPALT 0 0.1   
HK CV-X1-173  ASC IgG1 3-30 3 AKDYDSALCTGGTCTFDAFDF 27  1-27 1 QNYNSAPPWT 11  0.24   
HL CV-X1-174  ASC IgG1 3-21 6 ATVQGDYVAGRAYYYGMDV 0 3-1 2 QAWDSSTAV 0 0.10   
HK CV-X1-175  ASC IgG1 1-69 4 ARGLQGTHLDC 1 4-1 3 QQYYSTGFT 1 1.99 - n.t. 
HL CV-X1-177  ASC IgG1 3-30 4 ARAETPASEIDY 0 3-1 2 QAWDSSHVV 1 0.08   
HK CV-X1-178  ASC IgA1 3-49 6 TRDRPIDYGDLHIYYYGLDV 22  2-28 2 MQALQTPPT 8 0.1   
HK CV-X1-180  ASC IgA1 4-39 5 LKDRTLQGNWFDP 26  3-11 5 QQRRDWPPVT 14  0.09   
HL CV-X1-183 X1-1 ASC IgG1 3-30 4 ASKSPERGSFDY 26  2-14 1 SSYTNGSSLYV 7 n.exp.   
HL CV-X1-188  ASC IgM 4-4 5 AKGGGPIVA 14  4-60 2 ETWDSNTRL 8 0.08   
HL CV-X1-189  ASC IgG1 3-23 6 AKGRRYYDFWSGPMPYGMDV 1 2-14 3 SSYTSSSTLGV 10  0.09   
HL CV-X1-190 X1-1 ASC IgG1 3-30 4 ANTSPGRGSFDY 9 2-14 1 SSYTNSSTLYV 13  0.08   
HK CV-X1-191  ASC IgG1 4-31 4 ARQLRFLEWQYFDY 0 1-33 4 QQYDNLLT 0 n.exp.   
HK CV-X1-195  ASC IgA1 3-64 4 VKGWGVKASSLGGDY 20  3-11 4 HQRSDWPRLT 11  n.exp.   
HK CV-X2-103  S1-MBC IgA1 3-15 5 TTWRLGQDWFDP 17  1-39 4 QQSYSAPLT 14  0.81 ++ >250 
HL CV-X2-105  S1-MBC IgA1 3-73 6 TRRFDPNQRNDYYYALDF 12  1-44 1 SAWDDSLNGYV 9 3.48 + n.t. 
HK CV-X2-106  S1-MBC IgG1 1-69 6 ATRKETTVTTSLVYGMDV 1 1-39 2 QQSYSTPYT 2 9.14 ++ 250 
HK CV-X2-107 X2-2 S1-MBC IgA1 3-66 4 ARGKVGATGFEY 15  3-20 2 QQYGSSPPMYT 8 n.exp.   
HK CV-X2-108 X2-2 S1-MBC IgA1 3-66 4 ARGKVGATGFED 10  3-20 2 QQYGSSPPMYT 8 n.exp.   
HK CV-X2-109  S1-MBC IgM 5-51 3 ARLAHYYDRSGYSRADDAFDV 7 3-15 2 QQYNNWPPVYT 2 6.81 ++ >250 
HK CV-X2-117 X2-2 S1-MBC IgA1 3-66 4 ARGKVGATGFED 10  3-20 2 QQYGSSPPMYT 9 0.08   
HK CV-X2-118  S1-MBC IgG1 3-30 4 AKTGGPYCSGGSCYSALMDY 0 1-33 1 QQYDNLPPT 0 n.exp.   
HK CV-X2-123  S1-MBC IgA1 4-4 6 ARDRTREGYHDTLTGEFYFYGTDV 33  3-20 2 QQYAMSPVT 27  n.exp.   
.CC-BY-NC 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted August 16, 2020. . https://doi.org/10.1101/2020.08.15.252320doi: bioRxiv preprint 
63 
 
For clonality analysis mAbs from an identical donor were identified as clones when sharing the same V and J gene on both heavy and light 
chain and showing similarities within amino acid sequences of both CDR3. S1 reactivity was determined as a normalized optical density 
(OD) measured by SARS-CoV-2-S1 ELISA, with values above 0.5 considered as positive. From S1+ mAbs specificity to the RBD was 
determined using an RBD-ELISA and noted as negative (-), positive (+) or strongly positive (++), when detectable at 10 ng/ml. All strongly 
positive RBD+ mAbs were screened for neutralization of authentic SARS-CoV-2 (Fig. 1A), from which the IC50 was estimated. 
Abbreviations: ASC = antibody-secreting cell, S1-MBC = S1-SARS-CoV2-enriched memory B cell, Ig = immunoglobulin, HC = heavy chain, 
KC = kappa chain, LC = chain, IGHV/IGHJ = immunoglobulin heavy chain variable/joining gene, IGKV/IGKJ = immunoglobulin kappa chain 
variable/joining gene, IGLV/IGLJ = immunoglobulin lambda chain variable/joining gene, CDR = complementarity-determining region, SHM = 
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Supplementary Table ST3 | Public or common antibody response using VH3-53 and VH3-66 genes.  
mAb IGHV IGHJ CDR H3 IGKV/IGLV IGKJ/IGLJ CDR L3 
RBD-494 (Cao et al.) 3-53 6 ARDLVVYGMDV 1-9 4 QQLNSYPFT 
HK CV07-202 3-53*01 6*02 ARDLYYYGMDV 1-9*01 4*01 QQLNNYSVT 
HL CV07-275 3-66*01 4*02 ARDYYDSSGYYSSGGLGY 2-8*01 1*01 SSYAGSNNFV 
HL CV38-148 3-66*01 4*02 ARSAPLVGAYSGIYFDY 9-49*01 2*01 GADHGSGSNFVV 
HK CV38-221 3-66*01 4*02 ARGFGDYYFDY 3-20*01 2*01 QQLYT 
HK CV38-113 3-53*04 4*02 ARGGRLADAAGDY 1-33*01 2*02 QQYDNLPSWT 
HK CV38-139 3-53*01 4*02 ARGHYDLFDY 1-9*01 3*01 QQLNSYPPGT 
HL CV38-183 3-53*01 6*02 ARGDGWDNYYYGMDV 1-40*01 2*01 QSYDSSLSGSV 
HK CV-X1-126 3-53*04 6*02 ARDLSEGGMDV 1-12*01 4*01 QQANGFSAL 
Abbreviations: IGHV/IGHJ = immunoglobulin heavy chain variable/joining gene, IGKV/IGKJ = immunoglobulin kappa chain variable/joining 
gene. IGLV/IGLJ = immunoglobulin lambda chain variable/joining gene, CDR = complementarity-determining region.  
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Supplementary Table ST4 | Biophysical and functional characterization of the 18 most potent SARS-CoV-2 
















CV05-163 3.8 8.48 E+06 1.86 E-03 2.20 E-10 16.3 9.6 none 
CV07-200 9.0 n/a n/a n/a 14.5 none B / L* 
CV07-209 4.1 2.40 E+07 1.44 E-04 6.00 E-12 3.1 73.9 none 
CV07-222 5.5 2.98 E+07 2.07 E-04 6.97 E-12 7.8 36.9 B / L / C 
CV07-250 8.7 4.05 E+06 2.28 E-04 5.64 E-11 3.5 59.9 none 
CV07-255 4.8 n/a n/a n/a 14.5 51.6 L / H / C / K 
CV07-262 12.1 4.27 E+06 3.37 E-04 7.90 E-11 7.1 25.5 none 
CV07-270 14.2 n/a n/a n/a 82.3 7.5 L / H* / C 
CV07-283 4.0 1.52 E+07 7.24 E-04 4.75 E-11 16.9 38.0 none 
CV07-287 5.9 5.11 E+06 8.14 E-04 1.60 E-10 41.7 12.4 none 
CV07-315 7.2 2.36 E+07 2.62 E-04 1.12 E-11 24.9 none none 
CV38-113 5.2 2.33 E+06 3.12 E-04 1.34 E-10 20.8 51.2 none 
CV38-139 8.9 3.62 E+05 1.00 E-04 2.77 E-10 73.2 14.9 none 
CV38-142 5.6 6.31 E+05 6.60 E-04 1.05 E-09 23.2 26.9 none 
CV38-183 5.4 2.31 E+06 1.37 E-04 5.93 E-11 3.7 65.9 none 
CV38-221 6.4 7.45 E+05 3.71 E-04 4.99 E-10 172.6 50.1 none 
CV-X1-126 5.5 4.12 E+05 9.98 E-05 2.43 E-10 71.7 44.2 none 
CV-X2-106 5.6 n/a n/a n/a 17.6 19.9 none 
Abbreviations: EC50 = half-maximal effective concentration, Ka = association rate, Kd = dissociation rate, KD = equilibrium dissociation 
constant, IC50 = half-maximal inhibitory concentration, B = brain, L = lung, H = heart, C = colon, K = kidney. An asterisk (*) indicates weak 
binding. 
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Supplementary Table ST5 | X-ray data collection and refinement statistics.  
Data collection 
 CV07-250 + RBD CV07-270 + RBD 
Beamline SSRL 12-1 SSRL 12-1 
Wavelength (Å) 0.97946 0.97946 
Space group P 21 21 21 C 1 2 1 
Unit cell parameters   
a, b, c (Å) 68.0, 80.1, 153.7 157.0, 151.8, 66.0 
α, β, γ (°) 90, 90, 90 90, 95.4, 90 
Resolution (Å) a 50.0–2.55 (2.59–2.55) 50.0–2.70 (2.75–2.70) 
Unique reflections a 27,890 (2,659) 41,624 (2,089) 
Redundancy a 8.8 (6.5) 4.7 (3.6) 
Completeness (%) a 99.6 (98.9) 90.8 (90.8) 
<I/σI>
 a 17.3 (1.1) 6.7 (1.1) 
Rsym
b (%) a 11.9 (94.6) 19.9 (80.6) 
Rpim
b (%) a 4.1 (38.9) 9.9 (50.5) 
CC1/2
c (%) a 99.5 (71.0) 97.6 (67.6) 
Refinement statistics 
Resolution (Å) 43.2–2.55 49.7–2.72 
Reflections (work) 27,883 39,568 
Reflections (test) 2,656 2,055 
Rcryst
d / Rfree
e (%) 20.7/25.9 22.6/26.7 
No. of atoms 4,525 9,233 
Macromolecules 4,420 9,165 
Glycans 28 28 
Solvent 77 40 
Average B-value (Å2) 52 44 
Macromolecules 52 44 
Fab 46 42 
RBD 66 46 
Glycans 100 77 
Solvent 49 57 
Wilson B-value (Å2) 51 39 
RMSD from ideal geometry 
Bond length (Å) 0.005 0.007 
Bond angle (o) 0.74 1.27 
Ramachandran statistics (%) 
Favored 96.1 96.8 
Outliers 0.2 0.0 
PDB code 6XKQ 6XKP 
 
a Numbers in parentheses refer to the highest resolution shell. 
b Rsym = Σhkl Σi | Ihkl,i - <Ihkl> | / Σhkl Σi Ihkl,i and Rpim = Σhkl (1/(n-1))
1/2 Σi | Ihkl,i - <Ihkl> | / Σhkl Σi Ihkl,i, where Ihkl,i is the scaled intensity of the i
th 
measurement of reflection h, k, l, <Ihkl> is the average intensity for that reflection, and n is the redundancy. 
c CC1/2 = Pearson correlation coefficient between two random half datasets. 
d Rcryst = Σhkl | Fo - Fc | / Σhkl | Fo | x 100, where Fo and Fc are the observed and calculated structure factors, respectively. 
e Rfree was calculated as for Rcryst, but on a test set comprising 5% of the data excluded from refinement. 
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Supplementary Table ST6 | Hydrogen bonds and salt bridges identified at the antibody-RBD interface using the 
PISA program.  
CV07-250 Distance (Å) SARS-CoV-2 RBD 
Hydrogen bonds 
H:TYR98[N] 3.0 A:ALA475[O] 
H:ASN31[ND2] 3.4 A:SER477[OG] 
H:ASN100C[ND2] 3.8 A:GLY485[O] 
H:ASN100C[ND2] 2.9 A:PHE486[O] 
H:ASN97[ND2] 2.8 A:ASN487[OD1] 
H:ASN97[ND2] 2.7 A:TYR489[OH] 
H:TYR100B[N] 3.5 A:TYR489[OH] 
H:ASP96[OD1] 3.0 A:SER477[N] 
H:ASP96[OD2] 2.7 A:SER477[OG] 
H:ASP96[OD2] 3.5 A:THR478[N] 
H:ASP96[OD2] 2.9 A:THR478[OG1] 
H:SER95[OG] 2.9 A:ASN487[ND2] 
H:PHE100[O] 3.4 A:TYR489[OH] 
L:SER27A[OG] 3.2 A:TYR505[OH] 
L:HIS31[N] 3.1 A:GLN493[OE1] 
L:SER67[OG] 3.5 A:GLY446[O] 
L:GLY68[N] 3.1 A:GLY446[O] 
L:GLY68[N] 3.1 A:TYR449[OH] 
L:ASN69[N] 3.8 A:GLN498[OE1] 
L:ASN69[ND2] 3.7 A:GLN498[OE1] 
L:TYR49[OH] 3.5 A:PHE486[N] 
 
  
CV07-270 Distance (Å) SARS-CoV-2 RBD 
Hydrogen bonds 
H:TYR100B[OH] 2.8 A:SER349[OG] 
H:SER98[N] 3.2 A:GLY447[O] 
H:SER98[OG] 3.8 A:GLY447[O] 
H:SER98[OG] 3.2 A:ASN448[OD1] 
H:ARG100G[NH2] 2.9 A:GLU484[OE1] 
H:ARG100G[NH1] 3.2 A:GLU484[OE2] 
H:ARG100G[NH2] 3.0 A:GLU484[OE2] 
H:THR28[OG1] 3.2 A:LYS444[NZ] 
H:ASP31[OD1] 2.7 A:ARG346[NH1] 
H:ASP31[OD2] 2.7 A:LYS444[NZ] 
H:SER98[O] 2.7 A:TYR449[N] 
H:SER98[O] 3.3 A:ASN450[N] 
H:TYR100B[OH] 3.6 A:SER349[N] 
Salt bridges 
H:ARG100G[NH2] 2.9 A:GLU484[OE1] 
H:ARG100G[NH1] 3.2 A:GLU484[OE2] 
H:ARG100G[NH2] 3.0 A:GLU484[OE2] 
H:ASP31[OD1] 2.7 A:ARG346[NH1] 
H:ASP31[OD1] 3.4 A:ARG346[NE] 
H:ASP31[OD2] 2.7 A:LYS444[NZ] 
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P1 3 <5 1.0 0.0 1.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 
P2 3 <5 1.0 1.0 1.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 
P3 3 5 1.0 1.0 1.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
           
 
      
 
T1 3 10 1.5 1.0 1.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 
T2 3 25 3.0 2.5 2.0 3.5 3.5 4.0 0.0 3.0 2.0 1.5 0.0 2.0 2.0 3.8 1.0 0.8 
T3 3 15 2.0 2.0 2.0 2.0 0.0 0.0 0.0 2.0 1.0 0.0 1.0 1.0 0.0 0.0 0.5 0.5 
           
 
      
 
C1 3 15 2.5 2.0 2.0 3.0 2,5 3.0 0.0 3.0 1.0 2.0 1.0 1.0 2.0 3.0 0.5 1.5 
C2 3 20 2.5 2.5 2.0 2.5 2,5 3.0 0.0 2.0 1.0 0.0 3.0 1.5 2.0 3.0 0.5 1.5 
C3 3 20 2.5 2.0 2,5 2,5 2.0 2.0 0.0 3.0 2.0 0.0 2.0 1.0 2.0 2.0 1.0 1.0 
           
 
      
 
P4 5 5-10 2.0 2.0 2.0 1.5 0.0 0.0 0.0 2.0 2.0 0.0 1.5 1.0 0.0 0.0 1.0 0.8 
P5 5 <5 1.0 1.0 1.0 1.0 0.0 0.0 0.0 1.0 0.0 0.0 1.0 1.0 0.0 0.0 0.0 0.5 
P6 5 15 2.0 2.0 2.0 2.0 0.0 0.0 0.0 2.0 2.0 0.0 0.0 2.0 0.0 0.0 1.0 0.0 
           
 
      
 
T4 5 5-10 2.0 2.0 1.5 1.0 0.0 0.0 0.0 1.0 2.0 0.0 0.0 2.0 0.0 0.0 1.0 0.0 
T5 5 25 3.0 3.0 2.0 3.0 2.0 2.0 0.0 3.0 3.0 2.0 2.0 3.0 3.0 2.0 1.5 2.0 
T6 5 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
           
 
      
 
C4 5 80 4.0 4.0 3.0 3.0 3.0 3.0 3.0 3.0 4.0 3.0 3.5 3.0 3.5 3.0 3.5 3.3 
C5 5 15-20 2.5 3.0 2.5 2.0 2.0 2.0 1.5 2.0 2.0 2.5 0.0 3.0 2.0 2.0 1.8 1.3 
C6 5 50 4.0 3.5 3.0 3.0 3.0 3.0 4.0 2.5 4.0 3.5 4.0 3.5 3.0 3.0 4.0 3.8 
                   
P7 13 20 2.0 2.0 2.0 1.0 0.0 0.0 0.0 1.5 0.0 1.5 0.0 1.5 0.0 0.0 0.8 0.8 
P8 13 30 2.0 2.0 2.0 2.0 0.0 0.0 0.0 1.5 0.0 0.0 0.0 2.0 0.0 0.0 1.0 0.0 
P9 13 30 2.0 2.0 2.0 2.0 0.0 1.0 1.0 1.5 0.0 0.0 0.0 2.0 0.0 0.5 1.5 0.0 
                   
T7 13 15 2.0 2.0 2.0 1.5 0.0 0.0 0.0 1.5 0.0 0.0 0.0 2.0 0.0 0.0 1.0 0.0 
T8 13 5 1.0 1.5 1.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.5 0.0 
T9 13 20 1.5 1.5 1.0 1.5 0.0 0.0 0.0 1.0 0.0 0.0 0.0 1.5 0.0 0.0 0.8 0.0 
                    
C7 13 5 1.0 1.0 1.0 1.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.0 0.8 0.0 
C8 13 40 2.0 2.0 2.0 2.0 0.0 1.0 1.0 1.5 0.0 0.0 1.5 2.0 0.0 0.5 1.5 0.0 
C9 13 10 1.0 1.0 1.0 1.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 1.5 0.0 0.5 0.8 0.0 
Histopathological scoring of formalin-fixed paraffin-embedded lung tissue from hamsters of experimental groups as abbreviated (P = 
prophylactic, T = therapeutic, C = control) at indicated days post infection (dpi). Degree of inflammation (*) is scaled as (1) minimal, (2) mild, 
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(3) moderate or (4) severe. For all other parameters rating refers to occurrence rate from (1) sporadic, (2) mild, (3) moderate to (4) severe. 
Scores were assessed as means from parameters with corresponding letters as indicated. 
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